

GenCore version 5.1.3
Copyright (c) 1993 - 2003 Compunex Ltd.

OM protein - protein search, using sw model

Run on: January 13, 2003, 15:31:40 ; Search time 7.32042 Seconds

(without alignments)
612.211 Million cell updates/sec

Title: US-09-728-911-2

Perfect score: 1244

Sequence: 1 MMRHCFGLFSLFGLTVGA.....YQPMDDRSGRSERCVEIP 231

Scoring table:

BLOSUM62

Gapop 10.0, Gapext 0.5

Searched: 118974 seqs, 19401057 residues

118974

T number of hits satisfying chosen parameters:

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%
Listing first 45 summaries

Database:

Published Applications AA:*
1: /cgn2_6/ptodata/1/pubpaa/US08_NEW_PUB pep.*
2: /cgn2_6/ptodata/1/pubpaa/US06_NEW_PUB pep.*
3: /cgn2_6/ptodata/1/pubpaa/US07_NEW_PUB pep.*
4: /cgn2_6/ptodata/1/pubpaa/US07_PUBCOMB pep.*
5: /cgn2_6/ptodata/1/pubpaa/US07_PUBCOMB pep.*
6: /cgn2_6/ptodata/1/pubpaa/US07_PUBCOMB pep.*
7: /cgn2_6/ptodata/1/pubpaa/US08_PUBCOMB pep.*
8: /cgn2_6/ptodata/1/pubpaa/US08_PUBCOMB pep.*
9: /cgn2_6/ptodata/1/pubpaa/US09_NEW_PUB pep.*
10: /cgn2_6/ptodata/1/pubpaa/US09_PUBCOMB pep.*
11: /cgn2_6/ptodata/1/pubpaa/US10_NEW_PUB pep.*
12: /cgn2_6/ptodata/1/pubpaa/US10_PUBCOMB pep.*
13: /cgn2_6/ptodata/1/pubpaa/US60_NEW_PUB pep.*
14: /cgn2_6/ptodata/1/pubpaa/US60_PUBCOMB pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length DB	ID	Description
1	1244	100.0	231	10	US-09-728-911-2
2	1244	100.0	231	10	US-09-949-192-6
3	1130	90.8	210	10	US-09-728-911-13
4	336	27.0	207	10	US-09-746-359A-65
5	336	27.0	214	10	US-09-746-359A-63
6	336	27.0	217	10	US-09-746-359A-55
7	336	27.0	221	10	US-09-746-359A-12
8	336	27.0	542	9	US-10-028-072-188
9	336	27.0	542	12	US-10-052-586-398
10	336	27.0	547	10	US-09-746-359A-54
11	336	27.0	553	10	US-09-746-359A-11
12	336	27.0	553	10	US-09-949-192-7
13	336	27.0	559	10	US-09-746-359A-62
14	336	27.0	594	10	US-09-746-359A-53
15	336	27.0	594	10	US-09-746-359A-23
16	302	24.3	217	10	US-09-746-359A-38
17	302	24.3	514	10	US-09-746-359A-39
18	302	24.3	546	10	US-09-746-359A-37
19	289	23.2	56	10	US-09-864-761-40289

20	289	23.2	56	10	US-09-864-761-47623	Sequence 47623, A
21	266	21.4	574	9	US-09-912-672A-2	Sequence 2, App11
22	266	21.4	574	10	US-10-063-547-164	Sequence 164, App
23	266	21.4	574	10	US-09-728-911-25	Sequence 25, App1
24	266	21.4	574	10	US-09-870-574-4	Sequence 4, App1
25	266	21.4	574	12	US-10-006-867-164	Sequence 164, App
26	263	21.1	211	10	US-09-728-911-34	Sequence 34, App1
27	263	21.1	212	9	US-09-912-672A-5	Sequence 6, App11
28	263	21.1	560	9	US-09-912-672A-5	Sequence 6, App1
29	211	17.0	150	10	US-09-746-359A-56	Sequence 23, App1
30	174.5	14.0	308	9	US-09-912-672A-23	Sequence 20, App1
31	172	13.8	295	10	US-09-103-067-20	Sequence 3, App11
32	172	13.8	295	10	US-09-949-192-3	Sequence 3, App1
33	168.5	13.5	199	10	US-09-728-911-35	Sequence 35, App1
34	168.5	13.5	325	9	US-10-066-800-137	Sequence 137, App
35	168.5	13.5	325	10	US-09-870-574-3	Sequence 3, App11
36	168.5	13.5	325	10	US-09-949-192-5	Sequence 5, App1
37	168.5	13.5	325	10	US-09-949-192-5	Sequence 5, App1
38	164.5	13.2	196	10	US-09-746-359A-67	Sequence 390, App
39	164.5	13.2	201	9	US-09-912-672A-16	Sequence 67, App1
40	164.5	13.2	201	10	US-09-746-359A-59	Sequence 16, App1
41	164.5	13.2	203	10	US-09-746-359A-15	Sequence 15, App1
42	164.5	13.2	219	10	US-09-355-000-7	Sequence 7, App1
43	164.5	13.2	282	9	US-09-912-672A-15	Sequence 15, App1
44	164.5	13.2	307	10	US-09-746-359A-58	Sequence 58, App1
45	164.5	13.2	311	9	US-09-978-295A-352	Sequence 352, App

ALIGNMENTS

RESULT 1
US-09-728-911-2
Sequence 2, Application US/09728911
Parent No. US2002012669A1
GENERAL INFORMATION:
APPLICANT: Presnell, Scott R.
APPLICANT: Xu, Wenteng
APPLICANT: Kindvogel, Wayne
APPLICANT: Chen, Zhi
TITLE OF INVENTION: Human Cytokine Receptor
FILE REFERENCE: 99-93
CURRENT APPLICATION NUMBER: US/09/728,911
CURRENT FILING DATE: 2000-12-01
PRIOR APPLICATION NUMBER: US 60/169,049
PRIOR FILING DATE: 1999-12-03
PRIOR APPLICATION NUMBER: US 60/232,219
PRIOR FILING DATE: 2000-09-13
PRIOR APPLICATION NUMBER: US 60/244,610
NUMBER OF SEQ ID NOS: 36
SOFTWARE: FastSeq for Windows Version 3.0
SEQ ID NO 2
LENGTH: 231
TYPE: PRT
ORGANISM: Homo sapiens
US-09-728-911-2

Query Match 100.0%; Score 1244; DB 10; Length 231;
Best Local Similarity 100.0%; Pred. No. 8.3e-115;
Matches 231; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MMRHCFGLFSLFGLTVGAQSTHESIKPQVQFQSRNFHNIQWQGRALTGNSVY 60
DB 1 MMRHCFGLFSLFGLTVGAQSTHESIKPQVQFQSRNFHNIQWQGRALTGNSVY 60

QY 61 FVQYKYGQRQKKNKEDCGTQELSCDLSFTSDIOEYRVRVAASAGSYSEKSMRPF 120
DB 61 FVQYKYGQRQKKNKEDCGTQELSCDLSFTSDIOEYRVRVAASAGSYSEKSMRPF 120

QY 121 TPWWEKTKIDPVMNITQVNGSLVTLHA PNL PYRQYKQKNVSIIDYVELLYRVEFIINSL 180
DB 121 TPWWEKTKIDPVMNITQVNGSLVTLHA PNL PYRQYKQKNVSIIDYVELLYRVEFIINSL 180

Qy 181 EKEQYVEGAHRAVEIALTPHSSYCVVAEIQPMLDRRSQSEERCVEIP 231
 Db 181 EKEQYVEGAHRAVEIALTPHSSYCVVAEIQPMLDRRSQSEERCVEIP 231

RESULT 2

US-09-949-192-6
 ; Sequence 6, Application US/09949192
 ; Patent No. US20020142292A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Parham, Christi L.
 ; APPLICANT: Gorman, Daniel L.
 ; APPLICANT: Kurata, Hirokazu
 ; APPLICANT: Arai, Naoko
 ; APPLICANT: Sana, Theodore R.
 ; APPLICANT: Mattson, Jeanine D.
 ; APPLICANT: Murphy, Erin E.
 ; APPLICANT: Savkoor, Chetan
 ; APPLICANT: Grein, Jeffery
 ; APPLICANT: Smith, Kathleen M.
 ; APPLICANT: McManahan, Terrill K.
 ; TITLE OF INVENTION: MAMMALIAN GENES; RELATED REAGENTS AND METHODS
 ; FILE REFERENCE: DX01169K
 ; CURRENT APPLICATION NUMBER: US/09/949,192
 ; CURRENT FILING DATE: 2001-09-07
 ; PRIOR APPLICATION NUMBER: 60/231,267
 ; PRIOR FILING DATE: 2000-09-08
 ; NUMBER OF SEQ ID NOS: 53
 ; SOFTWARE: Patent in version 3.1
 ; SEQ ID NO 6
 ; LENGTH: 231
 ; TYPE: PRT
 ; ORGANISM: Homo sapiens
 US-09-949-192-6

Query Match 100.0%; Score 1244; DB 10; Length 231;
 Best Local Similarity 100.0%; Pred. No. 8.3e-115;
 Matches 231; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 MPPKCHFLGFLISFFLTGVTAGTQSTHESLKPORVQFQSRNPHNLOQPGRAITGNSVY 60
 Db 1 MPPKCHFLGFLISFFLTGVTAGTQSTHESLKPORVQFQSRNPHNLOQPGRAITGNSVY 60
 Qy 61 FVOYKIYQORQWKNKEDCWGTQELSCDLTSETSDIQEPYGRVRAAASAGSYSEWSMTPRF 120
 Db 61 FVOYKIYQORQWKNKEDCWGTQELSCDLTSETSDIQEPYGRVRAAASAGSYSEWSMTPRF 120
 Qy 121 TPWWTETKIDPPVNMNITQVNGSLLVILHAPNLPYRYQKEKNVSIEDYVELLYRVFIINSL 180
 Db 121 TPWWTETKIDPPVNMNITQVNGSLLVILHAPNLPYRYQKEKNVSIEDYVELLYRVFIINSL 180
 Qy 181 EKEQYVEGAHRAVEIALTPHSSYCVVAEIQPMLDRRSQSEERCVEIP 231
 Db 181 EKEQYVEGAHRAVEIALTPHSSYCVVAEIQPMLDRRSQSEERCVEIP 231

RESULT 3

US-09-728-911-13
 ; Sequence 13, Application US/09728911
 ; Patent No. US20020012669A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Presnell, Scott R.
 ; APPLICANT: Xu, Wenfeng
 ; APPLICANT: Kindsvogel, Wayne
 ; APPLICANT: Chen, Zhi
 ; TITLE OF INVENTION: Human Cytokine Receptor
 ; FILE REFERENCE: 99-93
 ; CURRENT APPLICATION NUMBER: US/09/728,911
 ; CURRENT FILING DATE: 2000-12-01
 ; PRIOR APPLICATION NUMBER: US 60/169,049
 ; PRIOR FILING DATE: 1999-12-03
 ; PRIOR APPLICATION NUMBER: US 60/232,219

; PRIOR FILING DATE: 2000-09-13
 ; PRIOR APPLICATION NUMBER: US 60/244,610
 ; PRIOR FILING DATE: 2000-10-31
 ; NUMBER OF SEQ ID NOS: 36
 ; SOFTWARE: FastSeq for Windows Version 3.0
 ; SEQ ID NO 13
 ; LENGTH: 210
 ; TYPE: PRT
 ; ORGANISM: Homo sapiens
 US-09-728-911-13

Query Match 90.8%; Score 1130; DB 10; Length 210;
 Best Local Similarity 100.0%; Pred. No. 1.1e-103;
 Matches 210; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 22 TQSTHESLKPORVQFQSRNPHNLOQPGRAITGNSVYFVOYKIYQORQWKNKEDCWGT 81
 Db 1 TQSTHESLKPORVQFQSRNPHNLOQPGRAITGNSVYFVOYKIYQORQWKNKEDCWGT 60
 Qy 82 QELSCDLTSETSDIQEPYGRVRAAASAGSYSEWSMTPRTPWWTETKIDPPVNMNITQVNGS 141
 Db 61 QELSCDLTSETSDIQEPYGRVRAAASAGSYSEWSMTPRTPWWTETKIDPPVNMNITQVNGS 120
 Qy 142 LLVILHAPNLPYRYQKEKNVSIEDYVELLYRVFIINSLSEKQYVEGAHRAVEIALTP 201
 Db 121 LLVILHAPNLPYRYQKEKNVSIEDYVELLYRVFIINSLSEKQYVEGAHRAVEIALTP 180
 Qy 202 HSSYCVVAEIQPMLDRRSQSEERCVEIP 231
 Db 181 HSSYCVVAEIQPMLDRRSQSEERCVEIP 210

RESULT 4

US-09-746-359A-65
 ; Sequence 65, Application US/09746359A
 ; Patent No. US20020042366A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Thompson, Penny
 ; APPLICANT: Foster, Donald C.
 ; APPLICANT: Xu, Wenfeng
 ; APPLICANT: Madden, Karen L.
 ; APPLICANT: Kelly, James D.
 ; APPLICANT: Sprecher, Cindy A.
 ; APPLICANT: Blumberg, Hal
 ; APPLICANT: Eagan, Maribeth A.
 ; APPLICANT: Jaspers, Stephen R.
 ; APPLICANT: Chandrasekhar, Yasmin A.
 ; APPLICANT: No. US20020042366A1ak, Julia E.
 ; TITLE OF INVENTION: Method for Treating Inflammation
 ; FILE REFERENCE: 99-108
 ; CURRENT APPLICATION NUMBER: US/09/746,359A
 ; CURRENT FILING DATE: 2001-05-21
 ; PRIOR APPLICATION NUMBER: 60/171,969
 ; PRIOR FILING DATE: 1999-12-23
 ; PRIOR APPLICATION NUMBER: 60/213,341
 ; PRIOR FILING DATE: 2000-06-22
 ; NUMBER OF SEQ ID NOS: 72
 ; SOFTWARE: FastSeq for Windows Version 3.0
 ; SEQ ID NO 65
 ; LENGTH: 207
 ; TYPE: PRT
 ; ORGANISM: Homo sapiens
 US-09-746-359A-65

Query Match 27.0%; Score 336; DB 10; Length 207;
 Best Local Similarity 37.2%; Pred. No. 9.5e-26;
 Matches 74; Conservative 33; Mismatches 90; Indels 2; Gaps 2;
 Qy 30 KPORVQFQSRNPHNLOQPGRAITGNSVYFVOYKIYQORQWKNKEDCWGTQELSCDLT 89
 Db 3 KPANITFLSINMKVNLQWTPPEGLQGVKVTYVQYFYQKWLKSKSECRINRYCDLS 62
 Qy 90 SETSDIQEPYGRVRAAASAGSYSEWSMTPRTPWWTETKIDPPVNMNITQVNGSLLVILHAP 149

GenCore version 5.1.3
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 13, 2003, 15:28:46 ; Search time 31.993 Seconds

(without alignments)
962.115 Million cell updates/sec

Title: US-09-728-911-2

Perfect score: 1244

Sequence: 1 MPMKCFGLFISFLTGVA.....YQMLDRRGRSERCVEIP 231

Scoring table:

BLOSUM62

Gapop 10.0, Gapext 0.5

Searched: 908470 seqs, 133250620 residues

T number of hits satisfying chosen parameters: 908470

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database:

A_Geneseq_101002:*

1: /SID52/gcgdata/geneseq/geneseq-emb1/AA1980.DAT:*

2: /SID52/gcgdata/geneseq/geneseq-emb1/AA1981.DAT:*

3: /SID52/gcgdata/geneseq/geneseq-emb1/AA1982.DAT:*

4: /SID52/gcgdata/geneseq/geneseq-emb1/AA1983.DAT:*

5: /SID52/gcgdata/geneseq/geneseq-emb1/AA1984.DAT:*

6: /SID52/gcgdata/geneseq/geneseq-emb1/AA1985.DAT:*

7: /SID52/gcgdata/geneseq/geneseq-emb1/AA1986.DAT:*

8: /SID52/gcgdata/geneseq/geneseq-emb1/AA1987.DAT:*

9: /SID52/gcgdata/geneseq/geneseq-emb1/AA1988.DAT:*

10: /SID52/gcgdata/geneseq/geneseq-emb1/AA1989.DAT:*

11: /SID52/gcgdata/geneseq/geneseq-emb1/AA1990.DAT:*

12: /SID52/gcgdata/geneseq/geneseq-emb1/AA1991.DAT:*

13: /SID52/gcgdata/geneseq/geneseq-emb1/AA1992.DAT:*

14: /SID52/gcgdata/geneseq/geneseq-emb1/AA1993.DAT:*

15: /SID52/gcgdata/geneseq/geneseq-emb1/AA1994.DAT:*

16: /SID52/gcgdata/geneseq/geneseq-emb1/AA1995.DAT:*

17: /SID52/gcgdata/geneseq/geneseq-emb1/AA1996.DAT:*

18: /SID52/gcgdata/geneseq/geneseq-emb1/AA1997.DAT:*

19: /SID52/gcgdata/geneseq/geneseq-emb1/AA1998.DAT:*

20: /SID52/gcgdata/geneseq/geneseq-emb1/AA1999.DAT:*

21: /SID52/gcgdata/geneseq/geneseq-emb1/AA2000.DAT:*

22: /SID52/gcgdata/geneseq/geneseq-emb1/AA2001.DAT:*

23: /SID52/gcgdata/geneseq/geneseq-emb1/AA2002.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1244	100.0	231	22	AAE05048
2	1244	100.0	231	22	AAE02460
3	1244	100.0	231	22	AAE02460
4	1244	100.0	231	22	AAE02460
5	1244	100.0	231	22	AAE02460
6	1244	100.0	231	22	AAE02460
7	1244	100.0	231	22	AAE02460
8	1244	100.0	231	22	AAE02460
9	1244	100.0	231	22	AAE02460
10	1244	100.0	231	22	AAE02460

11	1213	97.5	262	22	AAU09186	Human PRO19598 pol
12	1140	91.6	214	23	AAE17319	Human cytokine rec
13	1130	90.8	210	22	AAE02463	Human cytokine ext
14	1076	86.5	249	22	AAE02458	Human DNAX cytokin
15	1076	86.5	249	22	AAO17380	Human DNAX cytokin
16	687	55.2	130	22	AAE02461	Human cytokine rec
17	336	27.0	207	22	AAE05289	Human DNAX cytokin
18	336	27.0	207	22	AAE05289	Human IL-20 receptor
19	336	27.0	214	22	AAE05287	Human IL-20 receptor
20	336	27.0	214	22	AAE05287	Human IL-20 receptor
21	336	27.0	217	22	AAE05280	Human IL-20 receptor
22	336	27.0	217	22	AAE05280	Human IL-20 receptor
23	336	27.0	221	22	AAE05281	Human IL-20 receptor
24	336	27.0	221	22	AAE05281	Human IL-20 receptor
25	336	27.0	221	22	AAE05281	Human IL-20 receptor
26	336	27.0	221	22	AAE05281	Human IL-20 receptor
27	336	27.0	221	22	AAE05281	Human IL-20 receptor
28	336	27.0	221	22	AAE05281	Human IL-20 receptor
29	336	27.0	221	22	AAE05281	Human IL-20 receptor
30	336	27.0	221	22	AAE05281	Human IL-20 receptor
31	336	27.0	221	22	AAE05281	Human IL-20 receptor
32	336	27.0	221	22	AAE05281	Human IL-20 receptor
33	336	27.0	221	22	AAE05281	Human IL-20 receptor
34	336	27.0	221	22	AAE05281	Human IL-20 receptor
35	336	27.0	221	22	AAE05281	Human IL-20 receptor
36	336	27.0	221	22	AAE05281	Human IL-20 receptor
37	336	27.0	221	22	AAE05281	Human IL-20 receptor
38	336	27.0	221	22	AAE05281	Human IL-20 receptor
39	336	27.0	221	22	AAE05281	Human IL-20 receptor
40	336	27.0	221	22	AAE05281	Human IL-20 receptor
41	336	27.0	221	22	AAE05281	Human IL-20 receptor
42	336	27.0	221	22	AAE05281	Human IL-20 receptor
43	336	27.0	221	22	AAE05281	Human IL-20 receptor
44	336	27.0	221	22	AAE05281	Human IL-20 receptor
45	336	27.0	221	22	AAE05281	Human IL-20 receptor

ALIGNMENTS

RESULT 1	AAE05048	standard; Protein; 231 AA.
ID	AAE05048;	
AC	AAE05048;	
XX		
DT	10-SEP-2001 (first entry)	
XX		
DE	Human ZCYTO18 soluble receptor antagonist, zcytor16 protein.	
XX		
KW	Human; cytosolic; cytokine; ZCYTO18 protein; genetic abnormality;	
KW	cancer; inflammation; gene therapy; zcytor16.	
XX		
OS	Homo sapiens.	
XX		
PN	WO200146422-A1.	
XX		
PD	28-JUN-2001.	
XX		
PF	22-DEC-2000; 2000MO-US35308.	
XX		
PR	23-DEC-1999; 99US-0471767.	
XX		
PR	01-DEC-2000; 2000US-0250841.	
XX		
PA	(ZYMO) ZYMOGENETICS INC.	
XX		
PI	Prenell SR, Kindsvogel W;	
XX		
DR	WPI; 2001-408648/43.	
XX		
DR	N-PSDB; AAD09745.	
XX		
PT	Novel human cytokine polypeptide, ZCYTO18, useful for treating cancer -	
XX		

PS Example 13A; Page 158-159; 167pp; English.

XX The patent discloses novel human cytokine, ZCYTO18 protein and its

CC corresponding DNA. ZCYTO18 protein induces proliferation of cells

CC expressing zcytor11, a receptor for ZCYTO18 or induces cytotoxicity

CC in K5626 cells. ZCYTO18 DNA is useful for detecting a genetic

CC abnormality in a patient. ZCYTO18 DNA and its antibodies are useful

CC for detecting cancer and inflammation. ZCYTO18 protein is useful for

CC killing cancer cells. It is useful for increasing platelets in a

CC patient or injured tissue. It is also used in gene therapy.

CC The present sequence is human zcytor16, which is a naturally expressed

CC soluble receptor antagonist of ZCYTO18 protein.

XX Sequence 231 AA;

SQ Query Match 100.0%; Score 1244; DB 22; Length 231;

Best Local Similarity 100.0%; Pred. No. 1.1e-123;

Matches 231; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MPPKHCFLGFLISFFLTGVAGTOSTHESLKPORVQFSRNFHNILOMPGRALTGNSVY 60

DB 1 MPPKHCFLGFLISFFLTGVAGTOSTHESLKPORVQFSRNFHNILOMPGRALTGNSVY 60

QY 61 FVQYKIYGORQWKNEKDCWGTQELSCDLTSETSDIQEPYQGRVRAASAGSYSEWSMTPRF 120

DB 61 FVQYKIYGORQWKNEKDCWGTQELSCDLTSETSDIQEPYQGRVRAASAGSYSEWSMTPRF 120

QY 121 TPWETKIDPPVMNITQVNGSLVILHAPNLPRYQKEKNVSIEDYELLRVFIINNSL 180

DB 121 TPWETKIDPPVMNITQVNGSLVILHAPNLPRYQKEKNVSIEDYELLRVFIINNSL 180

QY 181 EKEQKYVEGAHRAVEIALTPHSSYCVVAEIIYQPMIDRRSQRSEERCVEIP 231

DB 181 EKEQKYVEGAHRAVEIALTPHSSYCVVAEIIYQPMIDRRSQRSEERCVEIP 231

RESULT 2

AAE02460

ID AAE02460 standard; Protein; 231 AA.

XX AAE02460;

AC AAE02460;

XX 10-AUG-2001 (first entry)

XX Human DNAX cytokine receptor subunit 4.2 (DCRS4.2).

XX Human; immunomodulator; DNAX cytokine receptor subunit 4.2; DCRS4.2;

KW therapy; immunological disorder; drug screening; cell development;

KW chromosome 6q24.1-25.2.

XX Homo sapiens.

XX Key Location/Qualifiers

FT Peptide 1..21

FT /label= Signal-peptide

FT Protein 22..231

FT /label= DCRS4.2

FT /notes= "Human mature DNAX cytokine receptor

FT subunit 4.2"

XX WO200136467-A2.

PN XX

XX 25-MAY-2001.

XX 16-NOV-2000; 2000WO-US31363.

XX 18-NOV-1999; 99US-0443060.

PR 13-DEC-1999; 99US-0170320.

XX (SCHE) SCHERING CORP.

XX Gorman DM;

PI XX

DR WPI; 2001-343800/36.

DR N-PSDB; AAD06414.

XX New mammalian receptor proteins related to cytokine receptors, useful

PT for regulating cell development and for diagnosis and treatment of

PT immunological disorders

XX Claim 3; Page 23; 124pp; English.

XX The present sequence is human DNAX cytokine receptor subunit 4.2

CC (DCRS4.2). DCRS4 gene is located on chromosome 6q24.1-25.2.

CC Cytokine receptors, fragments and antibodies are useful for treating

CC immunological disorders. DCRS3 (50R), DCRS4 (cytor) or fragments are

CC useful in drug screening to identify compounds having binding affinity

CC to the receptor subunit. Modulators of DCRs are useful for modulating

CC the physiology or development of a cell or tissue culture cells. A

CC purified DCRS is useful as a reagent to detect antibodies generated in

CC response to the presence of elevated levels of expression, or

CC immunological disorders which lead to production of antibody to the

CC endogenous receptor. Cytokine receptor sequences are useful as probes

CC for detecting levels of the cytokine receptor in patients suspected of

CC having an immunological disorder. Antibodies have therapeutic value, are

CC useful as potent antagonist, in detecting or quantifying ligands, for

CC isolating DCRS proteins and peptides, to screen expression libraries for

CC particular expression products, to raise anti-idiotypic antibodies and

CC for detecting or diagnosing various immunological conditions related to

CC expression of the protein or cells which express the protein.

XX Sequence 231 AA;

SQ Query Match 100.0%; Score 1244; DB 22; Length 231;

Best Local Similarity 100.0%; Pred. No. 1.1e-123;

Matches 231; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MPPKHCFLGFLISFFLTGVAGTOSTHESLKPORVQFSRNFHNILOMPGRALTGNSVY 60

DB 1 MPPKHCFLGFLISFFLTGVAGTOSTHESLKPORVQFSRNFHNILOMPGRALTGNSVY 60

QY 61 FVQYKIYGORQWKNEKDCWGTQELSCDLTSETSDIQEPYQGRVRAASAGSYSEWSMTPRF 120

DB 61 FVQYKIYGORQWKNEKDCWGTQELSCDLTSETSDIQEPYQGRVRAASAGSYSEWSMTPRF 120

QY 121 TPWETKIDPPVMNITQVNGSLVILHAPNLPRYQKEKNVSIEDYELLRVFIINNSL 180

DB 121 TPWETKIDPPVMNITQVNGSLVILHAPNLPRYQKEKNVSIEDYELLRVFIINNSL 180

QY 181 EKEQKYVEGAHRAVEIALTPHSSYCVVAEIIYQPMIDRRSQRSEERCVEIP 231

DB 181 EKEQKYVEGAHRAVEIALTPHSSYCVVAEIIYQPMIDRRSQRSEERCVEIP 231

RESULT 3

AAE02657

ID AAE02657 standard; Protein; 231 AA.

XX AAE02657;

XX 23-JUL-2001 (first entry)

XX Human cytokine receptor, zcytor16.

DE Human cytokine receptor, zcytor16.

XX Cytokine receptor; zcytor16; IL-TIF; antiinflammatory; cytostatic;

KW antirheumatic; antiarthritic; antiasthmatic; antiatherosclerotic;

KW immunosuppressive; chromosome 6q24.1-25.2; human.

XX Homo sapiens.

XX Key Location/Qualifiers

FT Domain 22..108

FT /note= "Ig domain 1"

FT Domain 22..231

FT /note= "extracellular domain"

FT Domain 112..210

FT /note= "Ig domain 2"
XX
PN WO200140467-A1.
XX
PD 07-JUN-2001.
XX
PF 01-DEC-2000; 2000WO-US32703.
XX
PR 03-DEC-1999; 99US-0169049.
XX 13-SEP-2000; 2000US-0232219.
PR 31-OCT-2000; 2000US-0244610.
XX
PA (ZYMO) ZYMOGENETICS INC.
XX
PI Presnell SR, Xu W, Kindsvogel W, Chen Z;
XX WPI; 2001-356158/37.
DR N-PSDB; AAF83735.
XX
PT New soluble cytokine receptor polypeptides and polynucleotides, useful
XX for diagnosing and treating cancer and inflammatory conditions -
PS Claim 1; Page 186-188; 210pp; English.
XX
XX The invention relates to a human cytokine receptor polypeptide,
CC designated zcytor16. The zcytor16 polypeptide can be expressed by
CC standard recombinant methodology and can bind to IL-11F (undefined). The
CC zcytor16 protein is useful for: inhibiting IL-11F induced proliferation
CC or differentiation of hematopoietic cell(s) (progenitors); reducing
CC IL-11F induced or IL-9 induced inflammation; and suppressing an
CC inflammatory response in a mammal with inflammation. Heteromeric/
CC multimeric receptor polypeptides such as soluble zcytor 16/CRF2-4 can be
CC used to reduce progression and symptoms of cancer. Zcytor16 polypeptides
CC can also be used to detect IL-11F levels which is indicative of
CC pathological conditions including inflammatory states (e.g. rheumatoid
CC arthritis) and cancer. Antibodies that bind zcytor16 polypeptides and the
CC polypeptides themselves are useful for the treatment of inflammation,
CC inflammatory diseases (e.g. infection, asthma, inflammatory bowel
CC disease, rheumatoid arthritis and atherosclerosis) and autoimmune
CC diseases. The antibodies and zcytor16 polynucleotides are also useful
CC for detecting cancer. The present sequence represents the human
XX zcytor16 protein.
XX
SQ Sequence 231 AA;
XX
Query Match 100.0%; Score 1244; DB 22; Length 231;
Best Local Similarity 100.0%; Pred. No. 1.1e-123;
Matches 231; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX 1 MNPKEHCFGLFISFLLTGVAAGTSTHESLKPORVQFOSRNPHNIIQWOPGRALTGNSSVY 60
DB 1 MNPKEHCFGLFISFLLTGVAAGTSTHESLKPORVQFOSRNPHNIIQWOPGRALTGNSSVY 60
XX
QY 61 FVQYKIYQGRQWKNKEDCGTQELSCDLTSETSDIOEPYGRVRAASAGSYSEMSMPRF 120
DB 61 FVQYKIYQGRQWKNKEDCGTQELSCDLTSETSDIOEPYGRVRAASAGSYSEMSMPRF 120
XX
QY 121 TPWMEETKIDPPVNNITQVNGSLVLIHAHPNLPYRYQEKKNVSIEDYELLRYVFIINSL 180
DB 121 TPWMEETKIDPPVNNITQVNGSLVLIHAHPNLPYRYQEKKNVSIEDYELLRYVFIINSL 180
XX
QY 181 EKEQKYVEGAHRAVEIEALTTPHSSYCVAAEIQPMLDRRSQREERCEVIEP 231
DB 181 EKEQKYVEGAHRAVEIEALTTPHSSYCVAAEIQPMLDRRSQREERCEVIEP 231
XX
RESULT 4
AA017381
ID AA017381 standard; Protein; 231 AA.
XX
AC AA017381;
XX
DT 08-AUG-2002 (first entry)

XX
DE Human cytokine receptor variant 2.
XX
XX Human; cytokine receptor; immune disease; psoriasis; cancer; infection;
KW rheumatoid arthritis; multiple sclerosis; Crohn's disease;
KW ulcerative colitis; transplant rejection; abortion; antipsoriatic;
KW immunosuppressive; antirheumatic; antiarthritic; neuroprotective;
KW antineoplastic; anticancer; cytostatic; dermatological;
XX chromosome 6q24.1-25.2; receptor.
XX
OS Homo sapiens.
XX
XX EPI191035-A2.
XX
XX 27-MAR-2002.
XX
XX 24-AUG-2001; 2001EP-0250307.
XX
XX 25-SEP-2000; 2000DE-1048626.
PR 17-NOV-2000; 2000DE-1058907.
PR 19-DEC-2000; 2000DE-1064906.
XX
XX (SCHD) SCHERING AG.
XX
XX Weiss B, Sabat R, Assadullah K, Toshi L;
XX WPI; 2002-332210/37.
DR N-PSDB; AAL46000.
XX
XX New nucleic acid encoding soluble cytokine receptor, useful for
XX diagnosis and treatment of e.g. immune disease, also related protein
XX and antibodies -
XX
PS Claim 6; Page 14; 21pp; German.
XX
XX The present invention provides the protein and coding sequences of 3
XX variants of a human cytokine receptor. The sequences can be used in the
XX diagnosis, prevention and treatment of immune diseases, including
XX psoriasis, cancer, chronic/life-threatening infections, rheumatoid
XX arthritis, multiple sclerosis, Crohn's disease, ulcerative colitis and
XX transplant rejection and in reproductive medicine, e.g. for diagnosing
XX abnormal immune reactions which cause abortions. The present sequence is
XX variant 2 of the invention.
XX
SQ Sequence 231 AA;
XX
Query Match 100.0%; Score 1244; DB 23; Length 231;
Best Local Similarity 100.0%; Pred. No. 1.1e-123;
Matches 231; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX 1 MNPKEHCFGLFISFLLTGVAAGTSTHESLKPORVQFOSRNPHNIIQWOPGRALTGNSSVY 60
DB 1 MNPKEHCFGLFISFLLTGVAAGTSTHESLKPORVQFOSRNPHNIIQWOPGRALTGNSSVY 60
XX
QY 61 FVQYKIYQGRQWKNKEDCGTQELSCDLTSETSDIOEPYGRVRAASAGSYSEMSMPRF 120
DB 61 FVQYKIYQGRQWKNKEDCGTQELSCDLTSETSDIOEPYGRVRAASAGSYSEMSMPRF 120
XX
QY 121 TPWMEETKIDPPVNNITQVNGSLVLIHAHPNLPYRYQEKKNVSIEDYELLRYVFIINSL 180
DB 121 TPWMEETKIDPPVNNITQVNGSLVLIHAHPNLPYRYQEKKNVSIEDYELLRYVFIINSL 180
XX
QY 181 EKEQKYVEGAHRAVEIEALTTPHSSYCVAAEIQPMLDRRSQREERCEVIEP 231
DB 181 EKEQKYVEGAHRAVEIEALTTPHSSYCVAAEIQPMLDRRSQREERCEVIEP 231
XX
RESULT 5
AA080000
ID AA080000 standard; Protein; 231 AA.
XX
AC AA080000;
XX

Mon Jan 13 15:37:26 2003

Db 181 EKEQKYEGAHRAVEIEALTPHSSYCVVAEIQPMLDRRSQSRSERCVEIP 231

RESULT 6
ABG34086
ID ABG34086 standard; Protein; 231 AA.
XX AC ABG34086;
XX AC ABG34086;
DT 15-JUL-2002 (first entry)
XX AC ABG34086;
DE Human Pro peptide #57.
XX AC ABG34086;
KW Human; PRO; secreted protein; transmembrane protein;
KW genetic disorder; tumour; cancer.
XX Homo sapiens.
XX WO200224888-A2.
XX PD 28-MAR-2002.
XX PF 29-AUG-2001; 2001WO-US27099.
XX PR 01-SEP-2000; 2000US-229896P.
XX PR 05-SEP-2000; 2000US-230621P.
XX PR 12-SEP-2000; 2000US-235147P.
XX PR 10-NOV-2000; 2000WO-US30873.
XX PR 12-JAN-2001; 2001US-261878P.
XX PR 16-JAN-2001; 2001US-261910P.
XX PR 16-JAN-2001; 2001US-261939P.
XX PR 16-JAN-2001; 2001US-262150P.
XX PR 25-JAN-2001; 2001US-264395P.
XX PR 02-FEB-2001; 2001US-266421P.
XX PR 09-FEB-2001; 2001US-267623P.
XX PR 28-FEB-2001; 2001WO-US06520.
XX PR 09-MAR-2001; 2001US-274399P.
XX PR 03-APR-2001; 2001US-280982P.
XX PR 04-APR-2001; 2001US-282129P.
XX PR 04-APR-2001; 2001US-282199P.
XX PR 09-MAY-2001; 2001US-290589P.
XX PR 25-MAY-2001; 2001WO-US17092.
XX PR 01-JUN-2001; 2001WO-US17800.
XX PR 20-JUN-2001; 2001WO-US19692.
XX PR 29-JUN-2001; 2001WO-US21066.
XX PR 09-JUL-2001; 2001WO-US21735.
XX (GETH) GENENTECH INC.
XX Baker KP, Eaton DL, Filvaroff B, Goddard A, Grimaldi JC;
PI Gurney AL, Smith V, Stephan J, Watanabe CK, Wood WI, Zhang Z;
PI Fong S;
XX WPI: 2002-362426/39.
XX N-PSDB; ABK70017.
XX New PRO polypeptides and polynucleotides encoding the polypeptides,
PT useful in gene therapy, chromosome identification, tissue typing, or
PT for genetic analysis of individuals with genetic disorders -
XX Claim 11; Figure 114; 218pp; English.
XX This invention relates to the cDNA and protein sequences of novel
XX secreted and transmembrane polypeptides PRO polypeptides. The
CC invention also comprises a method for producing the proteins of the
CC invention by recombinant means and antibodies specific for the protein
CC of the invention. The antibody may be used for detecting the PRO
CC proteins of the invention and may be used to modify their activity.
CC polynucleotides may be used as hybridisation probes for a cDNA library
CC to isolate the full-length PRO cDNA or to isolate other cDNAs, to
CC construct hybridisation probes for mapping the gene which encodes that
CC PRO and for genetic analysis of individuals with genetic disorders, in
CC assays to identify other proteins or molecules involved in binding

15-JUL-2002 (first entry)
Human IL-TIF/IL-22 binding protein #1.
Human, soluble protein; interleukin-TIF/IL-22; IL-TIF/IL-22; IL-22BP;
IL-TIF/IL-22 antagonist.
Homo sapiens.
WO200224912-A2.
28-MAR-2002.
21-SEP-2001; 2001WO-US29576.
22-SEP-2000; 2000US-234583P.
03-NOV-2000; 2000US-245495P.
31-JUL-2001; 2001US-0919162.
(LUDW-) LUDWIG INST CANCER RES.
Renauld J, Dumoutier L;
WPI: 2002-383190/41.
N-PSDB; ABK50076.
Polynucleotide and polypeptide of soluble protein which binds to
interleukin-TIF/IL-22 useful for inhibiting effect of IL-TIF/IL-22 on a
cell -
Claim 14; Page 39; 42pp; English.
The present invention relates to a new polynucleotide that encodes a
soluble protein which binds to interleukin (IL)-TIF/IL-22 (also referred
to as IL-22BP), where the complementary sequence of the invention
hybridises under stringent conditions to a nucleotide sequence of 2271
or 2366 base pairs, as given in the specification. The molecules of the
invention are useful for inhibiting (antagonising) effect of IL-TIF/IL-22
on a cell, for determining whether IL-TIF/IL-22 is present in a sample,
for inhibiting binding of IL-TIF/IL-22 to a binding partner, preferably
in vitro, and for obtaining an antibody molecule specific for the soluble
binding protein of the invention, from a population or panel of antibody
molecules of diverse binding specificity. The soluble protein is further
useful in manufacture of a medicament for treating an antibody or a peptide
disease and for assaying an agent, preferably an antibody or a peptide
fragment of IL-TIF/IL-22 or the soluble protein, that modulates binding
of the soluble protein to IL-TIF/IL-22, where the agent identified is
used in the manufacture of medicament for treating IL-TIF/IL-22 mediated
disorder. The antibody is useful for determining presence of the soluble
protein, where the antibody is detectably labelled. The present amino
acid sequence represents the human IL-TIF/IL-22 binding protein #1 of
the invention.

Query Match 100.0%; Score 1244; DB 23; Length 231;
Best Local Similarity 100.0%; Pred. No. 1.1e-123; Indels 0; Gaps 0;
Matches 231; Conservative 0; Mismatches 0;
Qy 1 MNPKHCFGLIFLIFLTVAGTSTHESLKPQVQSRNFHILQWQGRALTGNSVY 60
1 MNPKHCFGLIFLIFLTVAGTSTHESLKPQVQSRNFHILQWQGRALTGNSVY 60
Qy 61 FVQYKIYQORQWKNKDCWGTQELSCDLTSETSDIQEPYIGRVRASAGSYSEMSWTPRF 120
61 FVQYKIYQORQWKNKDCWGTQELSCDLTSETSDIQEPYIGRVRASAGSYSEMSWTPRF 120
Qy 121 TPWETKIDPPVNMITQVNGSLVILHAPNLPRYQKKNVSDIYVYLLRYFIINNSL 180
121 TPWETKIDPPVNMITQVNGSLVILHAPNLPRYQKKNVSDIYVYLLRYFIINNSL 180
Db 181 EKEQKYEGAHRAVEIEALTPHSSYCVVAEIQPMLDRRSQSRSERCVEIP 231

CC reaction, to generate transgenic animals or knock-out animals which in
CC turn are useful in the development and screening of therapeutically
CC useful reagents, for chromosome identification, and tissue typing. The
CC PRO polypeptides are useful in gene therapy, and as molecular weight
CC markers for protein electrophoresis purposes. The sequences may
CC also be used to detect overexpression on PRO polypeptides in cancerous
CC tumours and for screening for differentially expressed genes using
CC microarray technology. The present sequence represents a human PRO
CC protein of the invention.

XX Sequence 231 AA;

Query Match 100.0%; Score 1244; DB 23; Length 231;
Best Local Similarity 100.0%; Pred. No. 1,1e-123;
Matches 231; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MPRKHCFLGLISFPLTGVAGTOSTHESLKPORVQFSRNFNIIOMQGRALTGNSSVY 60
DB 1 MPRKHCFLGLISFPLTGVAGTOSTHESLKPORVQFSRNFNIIOMQGRALTGNSSVY 60
QY 61 FVOYKTYGQRQMKKEDCKGTOLSCDLTSETSDIOEPYGRVRAASAGSYSEWSMTPRF 120
DB 61 FVOYKTYGQRQMKKEDCKGTOLSCDLTSETSDIOEPYGRVRAASAGSYSEWSMTPRF 120
QY 121 TFWMETKIDPPVNNITOVNGSLVILHAPNLPYRQKKNVSIIDYVELLRVFIINNSL 180
DB 121 TFWMETKIDPPVNNITOVNGSLVILHAPNLPYRQKKNVSIIDYVELLRVFIINNSL 180
QY 181 EKEQKVEGAHRAVEIEALTPHSSYCVVAEITYOPMLDRSQRSEERCVEIP 231
DB 181 EKEQKVEGAHRAVEIEALTPHSSYCVVAEITYOPMLDRSQRSEERCVEIP 231

RESULT 7

ID AAE17320 standard; Protein; 231 AA.

AC AAE17320;

DT 18-APR-2002 (first entry)

DE Human cytokine receptor protein, sbg456548Cytora #2.

XX Human; therapy; wound healing disorder; vaccine; cancer; infection;
KW autoimmune disorder; hematopoietic disorder; inflammation; arthritis;
KW Parkinson's disease; Huntington's chorea; schizophrenia; antiarrhythmic;
KW multiple sclerosis; Alzheimer's disease; analgesic; cardiac; asthma;
KW ischaemia; stroke; bone disease; atherosclerosis; brain disorder;
KW depression; cardiovascular disease; myocardial infarction; renal failure;
KW respiratory disease; liver disorder; Fanconi's syndrome; spleen disorder;
KW type II diabetes mellitus; skeletal muscle disorder; immunosuppressive;
KW hyperlipidemia; renal disease; hypoglycaemia; gastrointestinal disease;
KW nocturnal; cirrhosis; Hodgkin's disease; neuroleptic; antiinflammatory;
KW haemostatic; vulnerrary; anticonvulsant; antithematic; neuroprotective;
KW nephrotropic; hypotensive; vasotropic; cyostatic; cerebroprotective;
KW allergy; cytokine receptor.

OS Homo sapiens.

XX WO200199342-A1.

XX 27-DEC-2001.

XX 22-JUN-2001; 2001WO-US19929.

XX 22-JUN-2000; 2000US-21316P.

XX 22-JUN-2000; 2000US-21316P.

XX (SMIK) SMITHKLINE BEECHAM CORP.

XX (SMIK) SMITHKLINE BEECHAM PLC.

XX (GLAX) GLAXO GROUP LTD.

PI Agarwal P, Cogswell JP, Kabnic KS, Lai Y, Martensen SA;

PI Murdock PR, Smith RF, Strum JC, Xiang Z, Xie Q, Rizni SK;
XX WPI: 2002-139783/18.
DR N-PsDB; AAD27815.

PT Novel secreted and membrane-associated polypeptides and polynucleotides
PT useful for preventing, ameliorating or correcting dysfunction or
PT abnormalities -
PS Claim 1; Page 132-133; 138pp; English.

XX The invention relates to secreted and membrane-associated polypeptides
CC and polynucleotides. The sequences of the invention are useful in
CC diagnostic assays for detecting diseases associated with inappropriate
CC activity or levels of these polynucleotides, and in identifying their
CC agonists and antagonists that are potentially useful in therapy. The
CC sequences of the invention are useful as vaccines for inducing
CC immunological response. The sequences of the invention are useful for
CC treating cancers, infections, autoimmune disorders, haematopoietic
CC disorders, wound healing disorders, cholesterol ester storage disease,
CC inflammation, congenital muscular dystrophy, junctional epidermolysis
CC bullosa, Parkinson's disease, Huntington's chorea, multiple sclerosis,
CC vitiligo, bacterial infections, Alzheimer's disease, asthma, arthritis,
CC septicemia, psoriasis, inflammatory bowel disease, transplant rejection,
CC graft versus host disease, ischaemia, stroke, acute respiratory disease
CC syndrome, restenosis, brain injury, AIDS, bone disease, atherosclerosis,
CC brain disorders including paraspranuclear palsy, myotonic dystrophy,
CC depression, anxiety disorders and sleep disorders, cardiovascular
CC diseases including congestive heart failure and myocardial infarction,
CC respiratory diseases including chronic obstructive pulmonary disease,
CC acute bronchitis and adult respiratory distress syndrome, liver disorders
CC including hypercholesterolaemia, hypertriglyceridaemia, cirrhosis, viral
CC and non-viral hepatitis, type II diabetes mellitus, renal disease
CC including acute and chronic renal failure, glomerulonephritis, Fanconi's
CC syndrome, cystinuria, skeletal muscle disorders including hypoglycaemia
CC and tendinitis, gastrointestinal diseases including intestinal
CC obstruction and tropical sprue, spleen disorders including hypersplenism,
CC Hodgkin's disease and malignant lymphoma, testicular cancer, male
CC reproductive diseases including low testosterone and male infertility.
CC The present sequence is human cytokine receptor.

XX Sequence 231 AA;

Query Match 100.0%; Score 1244; DB 23; Length 231;
Best Local Similarity 100.0%; Pred. No. 1,1e-123;
Matches 231; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MPRKHCFLGLISFPLTGVAGTOSTHESLKPORVQFSRNFNIIOMQGRALTGNSSVY 60
DB 1 MPRKHCFLGLISFPLTGVAGTOSTHESLKPORVQFSRNFNIIOMQGRALTGNSSVY 60
QY 61 FVOYKTYGQRQMKKEDCKGTOLSCDLTSETSDIOEPYGRVRAASAGSYSEWSMTPRF 120
DB 61 FVOYKTYGQRQMKKEDCKGTOLSCDLTSETSDIOEPYGRVRAASAGSYSEWSMTPRF 120
QY 121 TFWMETKIDPPVNNITOVNGSLVILHAPNLPYRQKKNVSIIDYVELLRVFIINNSL 180
DB 121 TFWMETKIDPPVNNITOVNGSLVILHAPNLPYRQKKNVSIIDYVELLRVFIINNSL 180
QY 181 EKEQKVEGAHRAVEIEALTPHSSYCVVAEITYOPMLDRSQRSEERCVEIP 231
DB 181 EKEQKVEGAHRAVEIEALTPHSSYCVVAEITYOPMLDRSQRSEERCVEIP 231

RESULT 8

ID AAU80324 standard; Protein; 263 AA.

AC AAU80324;

DT 15-JUL-2002 (first entry)

XX DE Human IL-TIF/IL-22 binding protein #2.
XX KW Human; soluble protein; interleukin-TIF/IL-22; IL-TIF/IL-22; IL-22BP;
KW IL-TIF/IL-22 antagonist.
XX OS Homo sapiens.
XX PN WO200224912-A2.
XX PD 28-MAR-2002.
XX PF 21-SEP-2001; 2001WO-US29576.
XX PR 22-SEP-2000; 2000US-234583P.
PR 03-NOV-2000; 2000US-245495P.
PR 31-JUL-2001; 2001US-091916Z.
XX PA (LUDW-) LUDWIG INST CANCER RES.
XX PI Renaud J, Dumoutier L;
XX WPI; 2002-383190/41.
DR N-PSDB; ABK50080.
XX Polynucleotide and polypeptide of soluble protein which binds to
PT interleukin-TIF/IL-22 useful for inhibiting effect of IL-TIF/IL-22 on a
PT cell -
XX
PS Claim 14; Page 41-42; 42pp; English.
XX The present invention relates to a new polynucleotide that encodes a
CC soluble protein which binds to interleukin (IL)-TIF/IL-22 (also referred
CC to as IL-22BP), where the complementary sequence of the invention
CC hybridises under stringent conditions to a nucleotide sequence of 2271
CC or 2366 base pairs, as given in the specification. The molecules of the
CC invention are useful for inhibiting (antagonising) effect of IL-TIF/IL-22
CC on a cell, for determining whether IL-TIF/IL-22 is present in a sample,
CC for inhibiting binding of IL-TIF/IL-22 to a binding partner, preferably
CC in vitro, and for obtaining an antibody molecule specific for the soluble
CC binding protein of the invention, from a population or panel of antibody
CC molecules of diverse binding specificity. The soluble protein is further
CC useful in manufacture of a medicament for treating an IL-22 mediated
CC disease and for assaying an agent, preferably an antibody or a peptide
CC fragment of IL-TIF/IL-22 or the soluble protein, that modulates binding
CC of the soluble protein to IL-TIF/IL-22, where the agent identified is
CC used in the manufacture of medicament for treating IL-TIF/IL-22 mediated
CC disorder. The antibody is useful for determining presence of the soluble
CC protein, where the antibody is detectably labelled. The present amino
CC acid sequence represents the human IL-TIF/IL-22 binding protein #2 of
CC the invention.
XX SQ Sequence 263 AA;
Query Match 97.9%; Score 1218; DB 23; Length 263;
Best Local Similarity 87.8%; Pred. No. 7.5e-121;
Matches 231; Conservative 0; Mismatches 0; Indels 32; Gaps 1;
QY 1 MPMKFLGLFLISFFLTGVAGTOSTHESLKPQVQVQSRNFHNLQWQPGRALTGSSVY 60
DB 1 MPMKFLGLFLISFFLTGVAGTOSTHESLKPQVQVQSRNFHNLQWQPGRALTGSSVY 60
QY 61 FVOYKI-----YGRQWKVKEDCWGTQELSCDL 88
DB 61 FVOYKIMFSCMSKSSHQSDVAMQHISCNPPGCGRTLAKYGRQWKVKEDCWGTQELSCDL 120
QY 89 TSSTSDIQEYGRVRAASAGSYSEWSMTFRPTPWETKIDPPVMNITQVNGSLVLHA 148
DB 121 TSSTSDIQEYGRVRAASAGSYSEWSMTFRPTPWETKIDPPVMNITQVNGSLVLHA 180
QY 149 PNLPRYQKEKNYSIEDYELLRYRFTIINNSLEKEQKVYEGAHRAVEIEALTPHSSYCVV 208
DB 181 PNLPRYQKEKNYSIEDYELLRYRFTIINNSLEKEQKVYEGAHRAVEIEALTPHSSYCVV 240

QY 209 AEIYQPMLEDRSRQSEERCVEIP 231
DB 241 AEIYQPMLEDRSRQSEERCVEIP 263
RESULT 9
AAE17321
ID AAE17321 standard; Protein; 263 AA.
XX AAE17321;
AC
XX 18-APR-2002 (first entry)
XX Human cytokine receptor protein, sbg45548CytRa #3.
XX Autoimmune disorder; wound healing disorder; vaccine; cancer; infection;
KW autoimmune disorder; haematopoietic disorder; inflammation; arthritis;
KW Parkinson's disease; Huntington's chorea; schizophrenia; antiarrhythmic;
KW multiple sclerosis; Alzheimer's disease; analgesic; cardiac; asthma;
KW ischaemia; stroke; AIDS; bone disease; atherosclerosis; renal failure;
KW depression; cardiovascular disease; myocardial infarction; renal failure;
KW respiratory disease; liver disorder; Fanconi's syndrome; spleen disorder;
KW type II diabetes mellitus; skeletal muscle disorder; immunosuppressive;
KW hypersplenism; renal disease; hypoglycaemia; gastrointestinal disease;
KW neutropenic; cirrhosis; Hodgkin's disease; neuroleptic; antiinflammatory;
KW haemostatic; vulnery; anticonvulsant; antirheumatic; neuroprotective;
KW nephrotropic; hypotensive; vasotropic; cytostatic; cerebroprotective;
KW allergy; cytokine receptor.
XX Homo sapiens.
XX WO200198342-A1.
XX 27-DEC-2001.
XX 22-JUN-2001; 2001WO-US19929.
XX 22-JUN-2000; 2000US-213156P.
XX 22-JUN-2000; 2000US-213161P.
XX (SMIK) SMITHKLINE BEECHAM CORP.
XX (SMIK) SMITHKLINE BEECHAM PLC.
XX (GLAX) GLAXO GROUP LTD.
XX Agarwal P, Cogswell JP, Kabnic KS, Lai Y, Martensen SA;
PI Murdock PR, Smith RF, Strum JC, Xiang Z, Xie Q, Rizni SK;
XX WPI; 2002-139783/18.
XX N-PSDB; AAD27816.
XX Novel secreted and membrane-associated polypeptides and polynucleotides
PT useful for preventing, ameliorating or correcting dysfunction or
PT disease including diabetes, cancer, hypertension and growth
PT abnormalities -
XX Claim 1; Page 133-134; 138pp; English.
XX The invention relates to secreted and membrane-associated polypeptides
CC and polynucleotides. The sequences of the invention are useful in
CC diagnostic assays for detecting diseases associated with inappropriate
CC activity or levels of these polynucleotides, and in identifying their
CC agonists and antagonists that are potentially useful in therapy. The
CC sequences of the invention are useful as vaccines for inducing
CC immunological response. The sequences of the invention are useful for
CC treating cancers, infections, autoimmune disorders, haematopoietic
CC disorders, wound healing disorders, cholesterol ester storage disease,
CC inflammation, congenital muscular dystrophy, junctional epidermolysis
CC bullosa, Parkinson's disease, Huntington's chorea, multiple sclerosis,
CC viral and bacterial infections, Alzheimer's disease, asthma, arthritis,
CC allergies, schizophrenia, sbg44245PROA-associated disorders,
CC septicemia, psoriasis, inflammatory bowel disease, transplant rejection,
CC graft verse host disease, ischaemia, stroke, acute respiratory disease

CC syndrome, restenosis, brain injury, AIDS, bone diseases, atherosclerosis,
 CC brain disorders including paraaortic/paracardiac palsy, myotonic dystrophy,
 CC depression, anxiety disorders and sleep disorders, cardiovascular
 CC diseases including congestive heart failure and myocardial infarction,
 CC respiratory diseases including chronic obstructive pulmonary disease,
 CC acute bronchitis and adult respiratory distress syndrome, liver disorders
 CC including hypercholesterolemia, hypertriglyceridemia, cirrhosis, viral
 CC and non-viral hepatitis, type II diabetes mellitus, renal disease
 CC including acute and chronic renal failure, glomerulonephritis, Fanconi's
 CC syndrome, cystinuria, skeletal muscle disorders including hypoglycaemia
 CC and tendinitis, gastrointestinal diseases including intestinal
 CC obstruction and tropical sprue, spleen disorders including hypersplenism,
 CC Hodgkin's disease and malignant lymphoma, testicular cancer, male
 CC reproductive diseases including low testosterone and male infertility.
 CC The present sequence is human cytokine receptor.

XX Sequence 263 AA;

Query Match

Best Local Similarity 97.9%; Score 1218; DB 23; Length 263;
 Chs 231; Conservative 0; Mismatches 0; Indels 32; Gaps 1;

QY 1 MPMKCFGLISFLVAGTOSTHESLKPRVQFQSRNFHNILOMOPGRALTGNSVY 60
 DB 1 MPMKCFGLISFLVAGTOSTHESLKPRVQFQSRNFHNILOMOPGRALTGNSVY 60
 QY 61 FVQYKI-----YGORQKNKEDCKGTOELSCDL 88
 DB 61 FVQYKIMFSCSMKSHQKPGCQWHSICNPGCRTLAKYGQRQKNKEDCKGTOELSCDL 120
 QY 89 TSETSDIOEPYGRVRAASAGSYSEMSWTPRFTPMWETKIDPPVNNITQVNSLLVILHA 148
 DB 121 TSETSDIOEPYGRVRAASAGSYSEMSWTPRFTPMWETKIDPPVNNITQVNSLLVILHA 180
 QY 149 PNLPRYQKEKNVSIEDYELLRVFIIINNSLEKEQKVEGAHRAVEIALTPHSSYCV 208
 DB 161 PNLPRYQKEKNVSIEDYELLRVFIIINNSLEKEQKVEGAHRAVEIALTPHSSYCV 240
 QY 209 AEIYQPMIDRRSRQSERCVEIP 231
 DB 241 AEIYQPMIDRRSRQSERCVEIP 263

RESULT 10

ID AA017382 standard; Protein: 263 AA.

XX AA017382;

XX 08-AUG-2002 (first entry)

XX Human cytokine receptor variant 3.

XX Human, cytokine receptor; immune disease; psoriasis; cancer; infection;
 KW rheumatoid arthritis; multiple sclerosis; Crohn's disease;
 KW ulcerative colitis; transplant rejection; abortion; antipsoriatic;
 KW immunosuppressive; antineumatic; antiarthritic; neuroprotective;
 KW antiinflammatory; antitumor; cytostatic; dermatological;
 KW chromosome 6q24.1-25.2; receptor.

XX Homo sapiens.

XX EP191035-A2.

XX 27-MAR-2002.

XX 24-AUG-2001; 2001EP-0250307.

XX 25-SEP-2000; 2000DE-1048626.

XX 17-NOV-2000; 2000DE-1058907.

XX 19-DEC-2000; 2000DE-1064906.

PA (SCHD) SCHERING AG.

XX Weis B, Sabat R, Assadullah K, Toshi L;
 PI WPI: 2002-332210/37.

XX DR N-PSDB; AAL46001.

PT New nucleic acid encoding soluble cytokine receptor, useful for
 PT diagnosis and treatment of e.g. immune disease, also related protein
 PT and antibodies

PS Claim 6; Page 15; 21pp; German.

XX The present invention provides the protein and coding sequences of 3
 CC variants of a human cytokine receptor. The sequences can be used in the
 CC diagnosis, prevention and treatment of immune diseases, including
 CC psoriasis, cancer, chronic/life-threatening infections, rheumatoid
 CC arthritis, multiple sclerosis, Crohn's disease, ulcerative colitis and
 CC transplant rejection and in reproductive medicine, e.g. for diagnosing
 CC abnormal immune reactions which cause abortions. The present sequence is
 CC variant 3 of the invention.

XX Sequence 263 AA;

Query Match

Best Local Similarity 97.6%; Score 1214; DB 23; Length 263;
 Matches 230; Conservative 1; Mismatches 0; Indels 32; Gaps 1;

QY 1 MPMKCFGLISFLVAGTOSTHESLKPRVQFQSRNFHNILOMOPGRALTGNSVY 60
 DB 1 MPMKCFGLISFLVAGTOSTHESLKPRVQFQSRNFHNILOMOPGRALTGNSVY 60
 QY 61 FVQYKI-----YGORQKNKEDCKGTOELSCDL 88
 DB 61 FVQYKIMFSCSMKSHQKPGCQWHSICNPGCRTLAKYGQRQKNKEDCKGTOELSCDL 120
 QY 89 TSETSDIOEPYGRVRAASAGSYSEMSWTPRFTPMWETKIDPPVNNITQVNSLLVILHA 148
 DB 121 TSETSDIOEPYGRVRAASAGSYSEMSWTPRFTPMWETKIDPPVNNITQVNSLLVILHA 180
 QY 149 PNLPRYQKEKNVSIEDYELLRVFIIINNSLEKEQKVEGAHRAVEIALTPHSSYCV 208
 DB 161 PNLPRYQKEKNVSIEDYELLRVFIIINNSLEKEQKVEGAHRAVEIALTPHSSYCV 240
 QY 209 AEIYQPMIDRRSRQSERCVEIP 231
 DB 241 AEIYQPMIDRRSRQSERCVEIP 263

RESULT 11

ID AAU09186 standard; Protein: 262 AA.

XX AAU09186;

XX 16-JUN-2002 (first entry)

XX Human PRO19598 polypeptide.

XX Human; PRO19598; clone DNA145887; immune-related disorder;
 KW inflammatory disorder; infectious disorder; immunodeficiency disorder;
 KW autoimmune disorder; renal disease; demyelinating disease; skin disease;
 KW neoplasia; transplantation associated disease; immunosuppressive;
 KW anti-inflammatory; antisthmatic; antidiabetic.

XX Homo sapiens.

XX Key

XX Peptide 1..20 Location/Qualifiers

XX Modified-site 17..22 /label= Signal_peptide

XX Modified-site 20..25 /note= "N-myristoylation site"

XX /note= "N-myristoylation site"

Protein 21..262
 /label= Mature_PRO19598_polypeptide
 Modified-site 55..58
 /note= "N-glycosylation site"
 Modified-site 165..168
 /note= "N-glycosylation site"
 Modified-site 170..173
 /note= "N-glycosylation site"
 Modified-site 191..194
 /note= "N-glycosylation site"
 Modified-site 208..211
 /note= "N-glycosylation site"
 Modified-site 220..225
 /note= "N-myristoylation site"
 WO200166740-A2.
 13-SEP-2001.
 01-MAR-2001; 2001WO-US06666.
 03-MAR-2000; 2000US-187202P.
 21-MAR-2000; 2000US-191015P.
 30-MAY-2000; 2000WO-US14941.
 05-JUN-2000; 2000US-209832P.
 24-AUG-2000; 2000WO-US23328.
 01-DEC-2000; 2000WO-US26678.
 (GETH) GENENTECH INC.
 Eaton DL, Fong S, Goddard A, Godowski PJ, Grimaldi CJ, Gurney AL;
 Tumas D, Watanabe CK, Wood WI, Zhang Z;
 WPI: 2001-625876/72.
 N-PSDB; AAS15368.
 Nucleic acids encoding PRO polypeptides, useful for detecting and
 treating immune related diseases and disorders in mammals including
 autoimmune diseases, inflammatory diseases and asthma -
 Claim 10; Fig 18; 122pp; English.
 The present invention relates to the isolation of 9 novel human PRO
 polypeptides and the cDNA sequences (AAS15360-AAS15368) encoding them.
 The novel PRO polypeptides include PRO1356, PRO1268, PRO1884, PRO3444,
 PRO3151, PRO4322, PRO9964, PRO10008 and PRO19598. The cDNA sequences
 encoding these PRO polypeptides have been designated as clones
 DNA64886-1601, DNA64903-1553, DNA84318-2520, DNA87997, DNA89273,
 DNA92223-2567, DNA96973, DNA101921 and DNA145887 respectively.
 Compositions (e.g. vaccines) containing PRO polypeptides and methods of
 using these compositions are useful in the treatment and diagnosis of
 immune-related disorders. Such disorders include immune-mediated
 inflammatory disorders (e.g. osteoarthritis), non-immune-mediated
 inflammatory disorders (e.g. diabetes mellitus), infectious disorders
 (e.g. granulomatous hepatitis), immunodeficiency disorders (e.g. AIDS),
 autoimmune disorders (e.g. rheumatoid arthritis), immune-related renal
 diseases (e.g. cirrhosis), demyelinating diseases of the peripheral or
 central nervous system (e.g. Guillain-Barre syndrome), immune-mediated
 skin diseases (e.g. contact dermatitis), neoplasias and transplantation
 associated diseases. The polynucleotide sequences of the invention may
 be used in gene therapy. AAU09178-AAU09186 represent the novel human
 PRO polypeptides of the invention.

Query Match 97.5%; Score 1213; DB 22; Length 262;
 Best Local Similarity 87.8%; Pred. No. 2.5e-120;
 Matches 230; Conservative 0; Mismatches 0; Indels 32; Gaps 1;
 2 MPKRCFLGLISFLTGAGTQSTHESLKQPVQFQSRNFHILQWPGRLTGNSVYF 61
 1 MPKRCFLGLISFLTGAGTQSTHESLKQPVQFQSRNFHILQWPGRLTGNSVYF 60

QY 62 VOYKI-----YQORWKNKEDCWCTOELSCDLT 89
 DB 61 VOYKIMFSCSMKSSHQKSPGQWQHISCNFPQCRTLAKYQORWKNKEDCWCTOELSCDLT 120
 QY 90 SETSDIQBPYGRVRAAGSAGSYSEMSMTPTPTWWTETKIDPPVMNITQVNGSLVILHAP 149
 DB 121 SETSDIQBPYGRVRAAGSAGSYSEMSMTPTPTWWTETKIDPPVMNITQVNGSLVILHAP 180
 QY 150 NLPYRYQKEKNVSIEDYYELLYRVFIINNSLEKEQKVYEGAHRAVEIEALTPHSSYCVVA 209
 DB 181 NLPYRYQKEKNVSIEDYYELLYRVFIINNSLEKEQKVYEGAHRAVEIEALTPHSSYCVVA 240
 QY 210 EYQPMLEDRRSORSERCEVEIP 231
 DB 241 EYQPMLEDRRSORSERCEVEIP 262

RESULT 12
 AAE17319
 ID AAE17319 standard; Protein; 214 AA.
 XX
 AC AAE17319;
 XX
 DT 18-APR-2002 (first entry)
 XX
 DE Human cytokine receptor protein, sbg456548CytoRa #1.
 XX
 KW Human; therapy: wound healing disorder; vaccine; cancer; infection;
 KW autoimmune disorder; haematopoietic disorder; inflammation; arthritis;
 KW Parkinson's disease; Huntington's chorea; schizophrenia; antiarrhythmic;
 KW multiple sclerosis; Alzheimer's disease; analgesic; cardiant; asthma;
 KW ischaemia; stroke; AIDS; bone disease; atherosclerosis; brain disorder;
 KW depression; cardiovascular disease; myocardial infarction; renal failure;
 KW respiratory disease; liver disorder; skeletal muscle disorder; immunosuppressive;
 KW type II diabetes mellitus; hypoglycaemia; gastrointestinal disease;
 KW hyperplasia; renal disease; Hodgkin's disease; neuroleptic; antiinflammatory;
 KW neoplastic; cirrhosis; anticonvulsant; antirheumatic; neuroprotective;
 KW haemostatic; hypotensive; vasotropic; cytotatic; cerebroprotective;
 KW nephrotropic; hypotensive; vasotropic; cytotatic; cerebroprotective;
 KW allergy; cytokine receptor.
 XX
 OS Homo sapiens.
 XX
 PN WO200198342-A1.
 XX
 PD 27-DEC-2001.
 XX
 PF 22-JUN-2001; 2001WO-US19929.
 XX
 PR 22-JUN-2000; 2000US-213156P.
 XX
 PR 22-JUN-2000; 2000US-213161P.
 XX
 XX (SMIK) SMITHKLINE BEECHAM CORP.
 XX (SMIK) SMITHKLINE BEECHAM PLC.
 XX (GLAX) GLAXO GROUP LTD.
 XX
 XX Agarwal P, Cogswell JP, Kabnic KS, Lai Y, Martensen SA;
 XX Murdock PR, Smith RF, Strum JC, Xiang Z, Xie Q, Rizni SK;
 XX WPI: 2002-139783/18.
 XX N-PSDB; AAD27814.
 XX
 PT Novel secreted and membrane-associated polypeptides and polynucleotides
 PT useful for preventing, ameliorating or correcting dysfunction or
 PT disease including diabetes, cancer, hypertension and growth
 PT abnormalities -
 XX
 PS Claim 1; Page 122; 138pp; English.
 XX
 CC The invention relates to secreted and membrane-associated polypeptides
 CC and polynucleotides. The sequences of the invention are useful in
 CC diagnostic assays for detecting diseases associated with inappropriate
 CC activity or levels of these polynucleotides, and in identifying their

CC agonists and antagonists that are potentially useful in therapy. The
 CC sequences of the invention are useful as vaccines for inducing
 CC immunological response. The sequences of the invention are useful
 CC for treating cancers, infections, autoimmune disorders, haematopoietic
 CC disorders, wound healing disorders, cholesterol ester storage disease,
 CC inflammation, congenital muscular dystrophy, junctional epidermolysis
 CC bullosa, Parkinson's disease, Huntington's chorea, multiple sclerosis,
 CC viral and bacterial infections, Alzheimer's disease, asthma, arthritis,
 CC allergies, schizophrenia, Sbg442445PPOA-associated disorder,
 CC septicemia, psoriasis, inflammatory bowel disease, transplant rejection,
 CC graft versus host disease, ischaemia, stroke, acute respiratory disease
 CC syndrome, restenosis, brain injury, AIDS, bone diseases, atherosclerosis,
 CC brain disorders including paraparesis, myotonic dystrophy,
 CC depression, anxiety disorders and sleep disorders, cardiovascular
 CC diseases including congestive heart failure and myocardial infarction,
 CC respiratory diseases including chronic obstructive pulmonary disease,
 CC acute bronchitis and adult respiratory distress syndrome, liver disorders
 CC including hypercholesterolemia, hypertriglyceridemia, cirrhosis, viral
 CC and non-viral hepatitis, type II diabetes mellitus, renal disease
 CC including acute and chronic renal failure, glomerulonephritis, Fanconi's
 CC syndrome, cystinuria, skeletal muscle disorders including hypoglycaemia
 CC and tendinitis, gastrointestinal diseases including intestinal
 CC obstruction and tropical sprue, spleen disorders including hypersplenism,
 CC Hodgkin's disease and malignant lymphoma, testicular cancer, male
 CC reproductive diseases including low testosterone and male infertility.
 CC The present sequence is human cytokine receptor.

CC Sequence 214 AA;

Query Match 91.6%; Score 1140; DB 23; Length 214;
 Best Local Similarity 100.0%; Pred. No. 1,1e-112;
 Matches 212; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 20 AGTSTHSLKPORQVQFSRNFHNLQWQGRALTGNSVYFQYKTYGQRQKNKEDCW 79
 DB 3 AGTOS-HESLXPRQVQFSRNFHNLQWQGRALTGNSVYFQYKTYGQRQKNKEDCW 62
 QY 80 GTQELSCDLTSETSDIOEPYGRVRAASAGSYSEMSMTPTPTPWEKIDPPVNNITQVNS 139
 DB 63 GTQELSCDLTSETSDIOEPYGRVRAASAGSYSEMSMTPTPTPWEKIDPPVNNITQVNS 122
 QY 140 GSLVILHAPNLPRYQKKNVSIEDYELLRYVFIINNSLEKQKYEGAGHRAVEIALTP 199
 DB 123 GSLVILHAPNLPRYQKKNVSIEDYELLRYVFIINNSLEKQKYEGAGHRAVEIALTP 182
 QY 200 TPSSYCVVAETIYQPMIDRRSQRSEERCVEIP 231
 DB 183 TPSSYCVVAETIYQPMIDRRSQRSEERCVEIP 214

RESULT 13

ID AAB62663 standard; Protein; 210 AA.

AC AAB62663;

DT 23-JUL-2001 (first entry)

DE Human zcytor16 extracellular domain fragment (residues 22-231).

KM Cytokine receptor; zcytor16; IL-TIF; antiinflammatory; cytostatic;
 KM antithematic; antiatherosclerotic; antiatherosclerotic;
 KM immunosuppressive; chromosome 6q24.1-25.2; human.

OS Homo sapiens.

PN WO200104067-A1.

PD 07-JUN-2001.

PF 01-DEC-2000; 2000WO-US32703.

PR 03-DEC-1999; 99US-0169049.

PR 13-SEP-2000; 2000US-0232219.
 PR 31-OCT-2000; 2000US-0244610.
 XX (ZYMO) ZYMOGENETICS INC.
 PA Presnell SR, Xu W, Kindsvogel W, Chen Z;
 PI WPI; 2001-356158/37.

PT New soluble cytokine receptor polypeptides and polynucleotides, useful
 for diagnosing and treating cancer and inflammatory conditions -
 PS Claim 1; Page 139; 210pp; English.

CC The invention relates to a human cytokine receptor polypeptide,
 CC designated zcytor16. The zcytor16 polypeptide can be expressed by
 CC standard recombinant methodology and can bind to IL-TIF (undefined). The
 CC zcytor16 protein is useful for: inhibiting IL-TIF induced proliferation
 CC or differentiation of hematopoietic cell(s) (progenitors); reducing
 CC IL-TIF induced or IL-9 induced inflammation; and suppressing an
 CC inflammatory response in a mammal with inflammation. Heteromeric/
 CC multimeric receptor polypeptides such as soluble zcytor 16/CRF2-4 can be
 CC used to reduce progression and symptoms of cancer. Zcytor16 polypeptides
 CC can also be used to detect IL-TIF levels which is indicative of
 CC pathological conditions including inflammatory states (e.g. rheumatoid
 CC arthritis) and cancer. Antibodies that bind zcytor16 polypeptides and the
 CC inflammatory diseases (e.g. infection, asthma, inflammatory bowel
 CC disease, rheumatoid arthritis and atherosclerosis) and autoimmune
 CC diseases. The antibodies and zcytor16 polynucleotides are also useful
 CC for detecting cancer. The present sequence represents the human zcytor16
 CC extracellular domain fragment.

CC Sequence 210 AA;

Query Match 90.8%; Score 1130; DB 22; Length 210;
 Best Local Similarity 100.0%; Pred. No. 1,2e-111;
 Matches 210; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 22 TOSTHSLKPORQVQFSRNFHNLQWQGRALTGNSVYFQYKTYGQRQKNKEDCWGT 81
 DB 1 TOSTHSLKPORQVQFSRNFHNLQWQGRALTGNSVYFQYKTYGQRQKNKEDCWGT 60
 QY 82 QELSCDLTSETSDIOEPYGRVRAASAGSYSEMSMTPTPTPWEKIDPPVNNITQVNS 141
 DB 61 QELSCDLTSETSDIOEPYGRVRAASAGSYSEMSMTPTPTPWEKIDPPVNNITQVNS 120
 QY 142 LVITLHAPNLPRYQKKNVSIEDYELLRYVFIINNSLEKQKYEGAGHRAVEIALTP 201
 DB 121 LVITLHAPNLPRYQKKNVSIEDYELLRYVFIINNSLEKQKYEGAGHRAVEIALTP 180
 QY 202 HSSYCVVAETIYQPMIDRRSQRSEERCVEIP 231
 DB 181 HSSYCVVAETIYQPMIDRRSQRSEERCVEIP 210

RESULT 14

ID AAE02458 standard; Protein; 249 AA.

AC AAE02458;

DT 10-AUG-2001 (first entry)

DE Human DNAX cytokine receptor subunit 4.1 (DCRS4.1).

KM Human; immunomodulator; DNAX cytokine receptor subunit 4.1; DCRS4.1;
 KM therapy; immunological disorder; drug screening; cell development;
 KM chromosome 6q24.1-25.2.


OS Homo sapiens.

XX Key

Location/Qualifiers

FT Peptide 1..21 /label= Signal-peptide
 FT Protein 22..249 /label= DCRS4.1
 FT /note= "Human mature DNAX cytokine receptor subunit 4.1"
 FT Modified-site 24 /note= "CK2 phosphorylation site"
 FT Modified-site 25 /note= "Calcium phosphorylation site"
 FT Modified-site 28 /note= "PKC phosphorylation site"
 FT Domain 31..70 /label= Cytokine_receptor_domain
 FT Modified-site 51 /note= "cAMP PK site"
 FT Modified-site 56 /note= "N-glycosylated"
 FT Disulfide-bond 78..86 /label= Conserved_disulphide_linkage
 FT Modified-site 81 /note= "Calcium phosphorylation site"
 FT Modified-site 85 /note= "Calcium phosphorylation site"
 FT Modified-site 89 /note= "Calcium phosphorylation site"
 FT Modified-site 92 /note= "Calcium phosphorylation site"
 FT Modified-site 100 /note= "Calcium phosphorylation site"
 FT Modified-site 110 /note= "Amidation site"
 FT Modified-site 118 /note= "Myristoyl site"
 FT Modified-site 119 /note= "PKC phosphorylation site"
 FT Modified-site 124 /note= "cAMP PK site"
 FT Modified-site 127 /note= "Myristoyl site"
 FT Modified-site 152 /note= "cAMP PK site"
 FT Modified-site 157 /note= "N-glycosylated"
 FT Modified-site 177 /note= "cAMP PK site"
 FT Modified-site 178 /note= "N-glycosylated"
 FT Modified-site 180 /note= "Calcium phosphorylation site"
 FT Modified-site 195 /note= "CK2 phosphorylation site"
 FT Modified-site 197 /note= "N-glycosylated"
 FT Modified-site 207 /note= "Calcium phosphorylation site"
 FT Modified-site 238 /note= "Myristoyl site"
 FT Modified-site 241 /note= "PKC phosphorylation site"
 FT Modified-site /note= "Calcium phosphorylation site"
 XX WO200136467-A2.
 XX 25-MAY-2001.
 XX 16-NOV-2000; 2000WO-US31363.
 XX 18-NOV-1999; 99US-0443060.
 PR 13-DEC-1999; 99US-0170320.

XX PA (SCHE) SCHERING CORP.
 XX Gorman DM;
 XX WPI; 2001-343800/36.
 DR N-PSDB; AAD06410.
 XX New mammalian receptor proteins related to cytokine receptors, useful for regulating cell development and for diagnosis and treatment of immunological disorders
 XX Claim 3; Page 22; 124pp; English.
 XX The present sequence is human DNAX cytokine receptor subunit 4.1 (DCRS4.1). DCRS4 gene is located on chromosome 6q24.1-25.2. Cytokine receptors, fragments and antibodies are useful for treating immunological disorders. DCRS3 (50R), DCRS4 (cytor) or fragments are useful in drug screening to identify compounds having binding affinity to the receptor subunit. Modulators of DCRS are useful for modulating the physiology or development of a cell or tissue culture cells. A purified DCRS is useful as a reagent to detect antibodies generated in response to the presence of elevated levels of expression, or immunological disorders which lead to production of antibody to the endogenous receptor. Cytokine receptor sequences are useful as probes for detecting levels of the cytokine receptor in patients suspected of having an immunological disorder. Antibodies have therapeutic value, are useful as potent antagonist, in detecting or quantifying ligands, for isolating DCRS proteins and peptides, to screen expression libraries for particular expression products, to raise anti-idiotypic antibodies and for detecting or diagnosing various immunological conditions related to expression of the protein or cells which express the protein.
 XX SQ Sequence 249 AA;
 Query Match 86.5%; Score 1076; DB 22; Length 249;
 Best Local Similarity 84.0%; Pred. No. 8.5e-106;
 Matches 210; Conservative 3; Mismatches 17; Indels 20; Gaps 3;
 QY 1 MNPKECFGLISPLTGVAGTQSTHESLKPQVQFOSRNFHNLQWPGRALTGNSVY 60
 DB 1 MNPKECFGLISPLTGVAGTQSTHESLKPQVQFOSRNFHNLQWPGRALTGNSVY 60
 QY 61 FVOYKIYQORQWKNKEDCWGTQELSCDLTSETSDIQEYVGRVRAASAGSYSEWS----- 115
 DB 61 FVOYKIYQORQWKNKEDCWGTQELSCDLTSETSDIQEYVGR-RGKNKNGNMPGPKQSK 119
 QY 116 -----MTPRFTPWWE--TKIDPPVNNITQVNGSLVTLHAPNLPYRYQKEKNV 161
 DB 120 RKSKGNQKNTVTAPAAKAFAGCAKIDPPVNNITQVNGSLVTLHAPNLPYRYQKEKNV 179
 QY 162 STEDYVELLYRVFIINNSLEKEQYVEGAHRAVEIETALTPHSSYCVVAEIQPMLDRSQ 221
 DB 180 STEDYVELLYRVFIINNSLEKEQYVEGAHRAVEIETALTPHSSYCVVAEIQPMLDRSQ 239
 QY 222 RSEERCVEIP 231
 DB 240 RSEERCVEIP 249
 RESULT 15
 AA017380
 ID AA017380 standard; Protein; 249 AA.
 XX AC AA017380;
 XX 08-AUG-2002 (first entry)
 XX Human cytokine receptor variant 1.
 XX Human; cytokine receptor; immune disease; psoriasis; cancer; infection;
 XX rheumatoid arthritis; multiple sclerosis; Crohn's disease;
 KW ulcerative colitis; transplant rejection; abortion; antipsoriatic;



GenCore version 5.1.3
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 13, 2003, 15:31:05 ; Search time 11.3873 Seconds

(without alignments)
596.865 Million cell updates/sec

Title: US-09-728-911-2

Sequence: 1 MPMHCFGLISFLTGVA.....YQPMIDRQRSERCVEIP 231

Scoring table:

BLOSUM62

Searched: 262574 seqs, 29422922 residues

Number of hits satisfying chosen parameters: 262574

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database:

Issued Patents AA:*
1: /cgnt_6/prodata/1/1aa/5A.COMB.pep:*
2: /cgnt_6/prodata/1/1aa/5B.COMB.pep:*
3: /cgnt_6/prodata/1/1aa/6A.COMB.pep:*
4: /cgnt_6/prodata/1/1aa/6B.COMB.pep:*
5: /cgnt_6/prodata/1/1aa/6C.COMB.pep:*
6: /cgnt_6/prodata/1/1aa/6D.COMB.pep:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	337	27.1	221	2	US-08-943-087-52
2	336	27.0	221	2	US-08-943-087-50
3	336	27.0	221	2	US-08-943-087-56
4	336	27.0	221	2	US-08-943-087-52
5	336	27.0	221	2	US-08-943-087-52
6	336	27.0	221	2	US-08-943-087-16
7	336	27.0	221	2	US-08-943-087-16
8	336	27.0	221	2	US-08-943-087-16
9	336	27.0	221	2	US-08-943-087-16
10	336	27.0	221	2	US-08-943-087-20
11	336	27.0	221	2	US-08-943-087-22
12	336	27.0	221	2	US-08-943-087-24
13	336	27.0	221	2	US-08-943-087-26
14	336	27.0	221	2	US-08-943-087-30
15	336	27.0	221	2	US-08-943-087-32
16	336	27.0	221	2	US-08-943-087-34
17	336	27.0	221	2	US-08-943-087-36
18	336	27.0	221	2	US-08-943-087-38
19	336	27.0	221	2	US-08-943-087-40
20	336	27.0	221	2	US-08-943-087-42
21	336	27.0	221	2	US-08-943-087-44
22	336	27.0	221	2	US-08-943-087-46
23	336	27.0	221	2	US-08-943-087-48
24	336	27.0	221	2	US-08-943-087-50
25	336	27.0	221	2	US-08-943-087-52
26	336	27.0	221	2	US-08-943-087-54
27	336	27.0	221	2	US-08-943-087-56

28	183.5	14.8	575	1	US-08-110-683-4	Sequence 4, Appli
29	183.5	14.8	575	2	US-08-477-166-4	Sequence 4, Appli
30	183.5	14.8	575	2	US-08-472-097-4	Sequence 4, Appli
31	183.5	14.8	575	2	US-08-472-097-4	Sequence 4, Appli
32	183.5	14.8	575	5	PCT-US93-11638-4	Sequence 4, Appli
33	181	14.5	559	1	US-08-424-788-3	Sequence 3, Appli
34	172	13.8	251	1	US-07-882-2028-2	Sequence 2, Appli
35	172	13.8	251	1	US-07-683-6828-4	Sequence 2, Appli
36	172	13.8	251	1	US-08-021-615A-2	Sequence 2, Appli
37	172	13.8	251	1	US-08-321-777-2	Sequence 2, Appli
38	172	13.8	251	1	US-08-463-931-6	Sequence 2, Appli
39	172	13.8	251	1	US-08-464-237A-4	Sequence 2, Appli
40	172	13.8	251	5	PCT-US92-02888A-4	Sequence 4, Appli
41	172	13.8	251	5	PCT-US93-04933-2	Sequence 4, Appli
42	172	13.8	295	1	US-08-463-931-2	Sequence 2, Appli
43	172	13.8	295	2	US-08-372-887-20	Sequence 20, Appli
44	172	13.8	295	4	US-09-224-048A-4	Sequence 4, Appli
45	168.5	13.5	325	2	US-08-683-743-4	Sequence 4, Appli

ALIGNMENTS

RESULT 1
US-08-943-087-52
Sequence 52, Application US/08943087
Patent No. 5945511
GENERAL INFORMATION:
APPLICANT: Lok, Si
APPLICANT: Kho, Choon J.
APPLICANT: Jernberg, Anna C.
APPLICANT: Adams, Robyn L.
APPLICANT: Whitmore, Theodore E.
APPLICANT: Parrish, Theresa M.
TITLE OF INVENTION: CYTOKINE RECEPTOR
NUMBER OF SEQUENCES: 60
CORRESPONDENCE ADDRESS:
ADDRESSEE: ZymoGenetics, Inc.
STREET: 1201 Eastlake Avenue East
CITY: Seattle
STATE: WA
COUNTRY: USA
ZIP: 98102
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FastSeq for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/943,087
FILING DATE:
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/803,305
FILING DATE: 20-FEB-1997
ATTORNEY/AGENT INFORMATION:
NAME: Lunn, Paul G
REGISTRATION NUMBER: 32,743
REFERENCE/DOCKET NUMBER: 96-24C1
TELECOMMUNICATION INFORMATION:
TELEPHONE: 206-442-6627
TELEFAX: 206-442-6678
TELEX:
INFORMATION FOR SEQ ID NO: 52:
SEQUENCE CHARACTERISTICS:
LENGTH: 221 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: protein
FRAGMENT TYPE: internal
US-08-943-087-52

Mon Jan 13 15:37:28 2003

Matches 74; Conservative 33; Mismatches 90; Indels 2; Gaps 2;

Query Match 27.1%; Score 337; DB 2; Length 221;
Best Local Similarity 37.2%; Pred. No. 3.le-29;
Matches 74; Conservative 33; Mismatches 90; Indels 2; Gaps 2;

QY 30 KPORVQFQRNFHILQWOPGRALTNSSVVFQYKIYQORQWKNKEDCWGTQELSCDLT 89
DB 10 KPGNITFUSIMKNKVLQWTPPEGLQGVKVTYVQYFIYGQKWLKSECRNINRTYCDLS 69
QY 90 SETSDIQEPYGRVRAASAGSYSEWSMTPTPTWETKIDPPVNMITQVNGSLVILHAP 149
DB 70 AETSDYEHQYAKVKAIMGTKCKWAESGRFYFPLETQIGPEVGLTTDKSISVVLTP 129
QY 150 NLPYRQKEKNVSIEDYY-ELLYRVFIINNSLEKEQKVYEGAHRAVEIEALTPHSSYCVW 208
DB 130 EKWKRNPEDLVPMQOIIYNSLKNVSVLNTKSNRTWSQCVTNHTLV-LTWLEPNTLYCVH 188
QY 209 AEIYQPMLDRRSRSEERC 227
DB 189 VESFVGPFPRAQPSKQC 207

RESULT 2

US-08-943-087-50
; Sequence 50, Application US/08943087
; Patent No. 5945511
; GENERAL INFORMATION:
; APPLICANT: Lok, Si
; APPLICANT: Kho, Choon J.
; APPLICANT: Jelmeberg, Anna C.
; APPLICANT: Adams, Robyn L.
; APPLICANT: Whitmore, Theodore E.
; APPLICANT: Farrah, Theresa M.
; TITLE OF INVENTION: CYTOKINE RECEPTOR
; NUMBER OF SEQUENCES: 60
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: ZymoGenetics, Inc.
; STREET: 1201 Eastlake Avenue East
; CITY: Seattle
; STATE: WA
; COUNTRY: USA
; ZIP: 98102
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/943,087
; FILING DATE:
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/803,305
; FILING DATE: 20-FEB-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Lunn, Paul G
; REGISTRATION NUMBER: 32,743
; REFERENCE/DOCKET NUMBER: 96-24C1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 206-442-6627
; TELEFAX: 206-442-6678
; TELEX:
; INFORMATION FOR SEQ ID NO: 50:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 221 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; FRAGMENT TYPE: internal
US-08-943-087-50

Query Match 27.0%; Score 336; DB 2; Length 221;
Best Local Similarity 37.2%; Pred. No. 4e-29;
Matches 73; Conservative 34; Mismatches 90; Indels 2; Gaps 2;

Matches 74; Conservative 33; Mismatches 90; Indels 2; Gaps 2;
QY 30 KPORVQFQRNFHILQWOPGRALTNSSVVFQYKIYQORQWKNKEDCWGTQELSCDLT 89
DB 10 KPGNITFUSIMKNKVLQWTPPEGLQGVKVTYVQYFIYGQKWLKSECRNINRTYCDLS 69
QY 90 SETSDIQEPYGRVRAASAGSYSEWSMTPTPTWETKIDPPVNMITQVNGSLVILHAP 149
DB 70 AETSDYEHQYAKVKAIMGTKCKWAESGRFYFPLETQIGPEVGLTTDKSISVVLTP 129
QY 150 NLPYRQKEKNVSIEDYY-ELLYRVFIINNSLEKEQKVYEGAHRAVEIEALTPHSSYCVW 208
DB 130 EKWKRNPEDLVPMQOIIYNSLKNVSVLNTKSNRTWSQCVTNHTLV-LTWLEPNTLYCVH 188
QY 209 AEIYQPMLDRRSRSEERC 227
DB 189 VESFVGPFPRAQPSKQC 207

RESULT 3

US-08-943-087-56
; Sequence 56, Application US/08943087
; Patent No. 5945511
; GENERAL INFORMATION:
; APPLICANT: Lok, Si
; APPLICANT: Kho, Choon J.
; APPLICANT: Jelmeberg, Anna C.
; APPLICANT: Adams, Robyn L.
; APPLICANT: Whitmore, Theodore E.
; APPLICANT: Farrah, Theresa M.
; TITLE OF INVENTION: CYTOKINE RECEPTOR
; NUMBER OF SEQUENCES: 60
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: ZymoGenetics, Inc.
; STREET: 1201 Eastlake Avenue East
; CITY: Seattle
; STATE: WA
; COUNTRY: USA
; ZIP: 98102
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/943,087
; FILING DATE:
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/803,305
; FILING DATE: 20-FEB-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Lunn, Paul G
; REGISTRATION NUMBER: 32,743
; REFERENCE/DOCKET NUMBER: 96-24C1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 206-442-6627
; TELEFAX: 206-442-6678
; TELEX:
; INFORMATION FOR SEQ ID NO: 56:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 221 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; FRAGMENT TYPE: internal
US-08-943-087-56

Query Match 27.0%; Score 336; DB 2; Length 221;
Best Local Similarity 36.7%; Pred. No. 4e-29;
Matches 73; Conservative 34; Mismatches 90; Indels 2; Gaps 2;

C;Accession: JC6311

Gene 186, 97-101, 1997
A;Title: CRF2-4: Isolation of cDNA clones encoding the human and mouse proteins.
A;Reference number: JC6311; MUID:97199375; PMID:9047351
A;Accession: JC6311
A;Status: preliminary
A;Molecule type: mRNA
A;Residues: 1-349 <GIB>
A;Cross-references: GB:U53596

Query Match 13.9%; Score 173; DB 2; Length 349;
Best Local Similarity 29.8%; Pred. No. 4.7e-08;
Matches 70; Conservative 30; Mismatches 93; Indels 42; Gaps 12;

QY 6 CFLGLSIFFLITGAGTQSTHESLKPORVQFQSRNPHNLOQW----PGRALTGSSVYF 61
DB 4 CVAGWLGGLLVPALGMP-----PPKVRMNSVFNKILQWEPAPFKTNLT-----FT 53

QY 62 VOYKIYQORQWKNKEDCWGTQELSCDLT--SETSDIOEPYIGRVRRAASAGSYSEWMTFR 119
DB 54 AQYESYRSFQ---DHCKRTASTQCFSHLSKYGD---YTVRVRABLADEHSEW-VNVT 104

QY 120 FPPWETKIDPPVNMITQVNGSLVILHAPNLPYQKE-----KNVSTEDYVELLYRV 173
DB 105 FCPVEDTIIGPEMQIESLELRSAPQI-----ENEPETWTLKNI-----YDSWAYRV 156

QY 174 -FIINLSLEKEQKVEGAHRAVEATLPHSSYCVABEIIYQPMIDRRSQRSERC 227
DB 157 QYWKNGTNEKFQV--SPYDSEVLNLEPWTYCIQVQGLLDQNRGTGENSEPIC 209

RESULT 3
KFH3
tissue factor precursor [validated] - human
N;Alternate names: coagulation factor III
C;Species: Homo sapiens (man)
C;Date: 30-Sep-1993 #sequence revision 30-Sep-1993 #text change 08-Dec-2000
C;Accession: A43645; A47574; A28320; A29062; A29672; A29008
R;MacKman, N.; Morrissey, J.H.; Fowler, B.; Edgington, T.S.
Biochemistry 28, 1755-1762, 1989

A;Title: Complete sequence of the human tissue factor gene, a highly regulated cellular
A;Reference number: A43645; MUID:89247359; PMID:2719931
A;Accession: A43645
A;Molecule type: DNA
A;Residues: 1-295 <MAC>
A;Cross-references: GB:J02846; NID:9339505; PIDN:AAA61152.1; PID:g339506
R;Fisher, K.L.; Gorman, C.M.; Vehar, G.A.; O'Brien, D.P.; Lawn, R.M.
Thromb. Res. 48, 89-99, 1987

A;Title: Cloning and expression of human tissue factor cDNA.
A;Reference number: A47574; MUID:88100453; PMID:3424286
A;Accession: A47574
A;Molecule type: mRNA
A;Residues: 1-295 <PIS>
A;Cross-references: GB:M27436; NID:9339507; PIDN:AAA36734.1; PID:g339508
R;Spicer, E.K.; Horton, R.; Bloem, L.; Bach, R.; Williams, K.R.; Guha, A.; Kraus, J.; Li
Proc. Natl. Acad. Sci. U.S.A. 84, 5148-5152, 1987

A;Title: Isolation of cDNA clones coding for human tissue factor: primary structure of
A;Reference number: A94171; MUID:87260946; PMID:3037536
A;Accession: A28320
A;Molecule type: mRNA
A;Residues: 1-295 <SPI>
A;Cross-references: GB:J02931; NID:9339501; PIDN:AAA61150.1; PID:g339502
R;Morrissey, J.H.; Fakhrai, H.; Edgington, T.S.
Cell 50, 129-135, 1987

A;Title: Molecular cloning of the cDNA for tissue factor, the cellular receptor for the
A;Reference number: A29062; MUID:87244317; PMID:3297348
A;Accession: A29062
A;Molecule type: mRNA
A;Residues: 1-295 <WOR>
A;Cross-references: GB:J02931; NID:9339501; PIDN:AAA61150.1; PID:g339502
R;Scarpati, E.M.; Wen, D.; Broze Jr., G.J.; Miletic, J.P.; Flandermeyer, R.R.; Siegel,
Biochemistry 26, 5234-5238, 1987

A;Title: Human tissue factor: cDNA sequence and chromosome localization of the gene.

A;Reference number: A29672; MUID:88050796; PMID:2823875
A;Accession: A29672
A;Molecule type: mRNA
A;Residues: 1-259, 'A', 261-295 <SCA>
A;Cross-references: GB:M16553; NID:g339503; PIDN:AAA61151.1; PID:g339504
R;Bach, R.; Konigsberg, W.H.; Nemerson, Y.
Biochemistry 27, 4227-4231, 1988

A;Title: Human tissue factor contains thioester-linked palmitate and stearate on the cyt
A;Reference number: A37422; MUID:8900604; PMID:3166978
A;Content: annotation; disulfide bonds and fatty acid binding site
C;Comment: Tissue factor is an integral membrane glycoprotein that serves as a receptor
C;Comment: Expression of tissue factor can be induced in a variety of tissues by certain
C;Genetics:
A;Gene: GDB:F3
A;Cross-references: GDB:119895; OMIM:134390
A;Map position: lp22-1p21
A;Introns: 34/1; 71/2; 138/1; 197/3; 251/1
C;Superfamily: tissue factor
C;Keywords: blood coagulation; glycoprotein; lipoprotein; thiolester bond; transmembrane
F;1-32/Domain: signal sequence #status predicted <SIG>
F;33-295/Product: tissue factor #status experimental <MAT>
F;33-251/Domain: extracellular #status predicted <EXT>
F;252-274/Domain: transmembrane #status predicted <TM>
F;275-295/Domain: intracellular #status predicted <INT>
F;43/Binding site: carbohydrate (Asn) (covalent) #status experimental
F;81-89, 218-241/Disulfide bonds: #status experimental
F;156,169/Binding site: carbohydrate (Asn) (covalent) #status predicted
F;277/Binding site: palmitate (Cys) (covalent) #status experimental

Query Match 13.8%; Score 172; DB 1; Length 295;
Best Local Similarity 25.3%; Pred. No. 4.6e-08;
Matches 59; Conservative 45; Mismatches 103; Indels 26; Gaps 12;

QY 11 LISFLITGAGTQSTHESLKPORVQFQSRNPHNLOQWGRALTGSSVYFQYKIYQOR 70
DB 21 LLGWFAQVAGAGTTTAAAYNLTKSTNFKTLEWPKPV---NQYTVQIST-KSG 75

QY 71 QWKNKEDCWGTQELSCDLTS-TSDIOEPYIGRV-----RAASAGSYSE--WSMTFRPT 121
DB 76 DWKSK-CFYITDTECDLTDEIVKDVQVTLAKVFSYPAGNVSTGSGEPLYSPEET 133

QY 122 PWEYTKI-DPPVNMITQVNGSLVILHAPNLPYQKEKNVSTEDYV--ELLVRFVIIN 178
DB 134 PYLETNLQPTIQSFEQVGTKNVTVDEDTLVR--RNNTFLSLRDVFGKDLITLYWKS 192

QY 179 SLEKEQKVEGAHR-AVEIEALTPHSSYCV--VVAEIIYQPMIDRRSQRSERCV 228
DB 193 SSSGKTKTAKTNTNEFLIIVD---KGENYCVSVQAVIPSRVNRKSTDSPEECM 242

RESULT 4
A47003
Cytokine receptor family class II protein CRF2-4 precursor - human
C;Species: Homo sapiens (man)
C;Date: 09-Sep-1994 #sequence revision 09-Sep-1994 #text change 01-Dec-2000
C;Accession: A47003; G01418
R;Lutfalla, G.; Gardiner, K.; Uze, G.
Genomics 16, 366-373, 1993

A;Title: A new member of the cytokine receptor gene family maps on chromosome 21 at leas
A;Reference number: A47003; MUID:93300510; PMID:8314576
A;Accession: A47003
A;Status: preliminary
A;Molecule type: mRNA
A;Residues: 1-325 <LUT>
A;Cross-references: GB:Z17227; NID:g3393378; PIDN:CAA78933.1; PID:g9393379
R;Lutfalla, G.
submitted to the EMBL Data Library, April 1994
A;Reference number: G06935
A;Accession: G01418
A;Status: preliminary; translated from GB/EMBL/DBJ
A;Molecule type: DNA
A;Residues: 1-123, 'D', 125-268, 'VGRME', <LUT>
A;Cross-references: EMBL:U08988; NID:g571295; PID:g571296

GenCore version 5.1.3
Copyright (c) 1993 - 2003 Compen Ltd.

OM protein - protein search, using sw model

Run on: January 13, 2003, 15:28:46 ; Search time 7.0493 Seconds

(without alignments)
1359.147 Million cell updates/sec

Title: US-09-728-911-2

Sequence: 1 MPMKFCFLGFLISFLTGVA.....YQPMIDRRSQSERECVEIP 231

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 112892 segs, 41476328 residues

T: number of hits satisfying chosen parameters: 112892

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database: SwissProt_40:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	183.5	14.8	575	110R_MOUSE	Q61727 mus musculu
2	173	13.9	349	110S_MOUSE	Q61190 mus musculu
3	172	13.8	295	1F_HUMAN	P13726 homo sapien
4	168.5	13.5	325	110S_HUMAN	O08334 homo sapien
5	165	13.3	560	1NRI_BOVIN	O04790 bos taurus
6	159	12.8	578	110R_HUMAN	Q13651 homo sapien
7	150.5	12.1	289	1F_CAVPO	Q91188 cavia porce
8	150.5	12.1	292	1F_BOVIN	P30331 bos taurus
9	148.5	11.9	590	1NRI_MOUSE	P33896 bos musculu
10	144.5	11.6	560	1NRI_SHEEP	Q28589 ovis aries
11	143.5	11.5	557	1F_RABIT	P24055 oryctolagus
12	143.5	11.5	292	1NRI_HUMAN	P17181 homo sapien
13	142.5	11.5	295	1F_RAT	P42533 rattus norv
14	138.5	11.1	489	1NRI_HUMAN	P15260 homo sapien
15	138	11.1	294	1F_MOUSE	P20352 mus musculu
16	123	9.9	536	1NRI_SHEEP	Q95207 ovis aries
17	119	8.7	530	1NRI_BOVIN	Q95141 bos taurus
18	108.5	8.6	515	1NRI_HUMAN	P48551 homo sapien
19	107	8.6	337	1NRI_HUMAN	P38484 homo sapien
20	98	7.9	477	1NRI_HUMAN	P33005 gallus galli
21	97.5	7.8	676	1KALM_CHICK	P32226 mus musculu
22	96.5	7.3	272	1VC06_SPKA	P32226 mus musculu
23	91	7.3	272	1VC06_SPKA	P32226 mus musculu
24	90	7.2	272	1VC06_SPKA	P32226 mus musculu
25	90	7.2	272	1VC06_SPKA	P32226 mus musculu
26	89.5	7.2	2215	1SORL_MOUSE	Q95209 o sortilin-
27	87.5	7.0	2215	1SORL_MOUSE	Q95209 o sortilin-
28	86	6.9	2214	1SORL_MOUSE	Q95209 o sortilin-
29	84	6.8	792	1RIRI_HUMAN	Q92673 h sortilin-
30	83	6.7	1259	1CAML_RAT	P23921 homo sapien
31	82.5	6.6	478	1HLYA_ECOLI	O05695 rattus norv
32	82	6.6	894	1GHR_HUMAN	P09986 escherichia
33	81.5	6.6	638	1GHR_HUMAN	P42263 homo sapien
					P79194 macaca mula

34	81.5	6.6	1260	1	CAML_MOUSE	P11627 mus musculu
35	81.5	6.6	1377	1	NEOI_RAT	P97603 rattus norv
36	81.5	6.6	1493	1	NEOI_MOUSE	P97798 mus musculu
37	81	6.5	606	1	2214_HUMAN	O9159 homo sapien
38	81	6.5	888	1	GLR3_RAT	P19492 rattus norv
39	80.5	6.5	478	1	HLXD_ECOLI	P67739 escherichia
40	80	6.4	716	1	HEPA_HSVB	P28946 equine herp
41	79.5	6.4	401	1	AMPQ_PSYIM	O05465 psychrobact
42	79.5	6.4	1411	1	Y297_HUMAN	O15040 homo sapien
43	79	6.4	680	1	KALM_HUMAN	P23352 homo sapien
44	78.5	6.3	529	1	121R_MOUSE	O9183 mus musculu
45	78.5	6.3	1461	1	NEOI_HUMAN	Q92859 homo sapien

ALIGNMENTS

RESULT 1
ID 110R_MOUSE STANDARD: PRT: 575 AA.

AC 061727
DT 15-JUL-1998 (Rel. 36, Created)
DT 15-JUL-1998 (Rel. 36, Last sequence update)
DT 16-OCT-2001 (Rel. 40, Last annotation update)
DE Interleukin-10 receptor alpha chain precursor (IL-10R-A) (IL-10R1).
GN IL10RA OR IL10R.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN (1)
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6 X AJ FL; TISSUE=Hematopoietic;
RX MEDLINE=94068585; PubMed=8248239;
RA Ho A.S.-Y., Liu Y., Khan T.A., Hsu D.-H., Bazan J.F., Moore K.W.;
RT "A receptor for interleukin 10 is related to interferon receptors."
RL Proc. Natl. Acad. Sci. U.S.A. 90:11267-11271(1993).
CC -1- FUNCTION: RECEPTOR FOR IL-10; BINDS IL-10 WITH A HIGH AFFINITY.
CC -1- SUBCELLULAR LOCATION: Type I membrane protein.
CC -1- SIMILARITY: BELONGS TO THE CLASS II CYTOKINE FAMILY OF RECEPTORS.

CC This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See <http://www.isb-sib.ch/announce/> or send an email to license@isb-sib.ch).

CC EMBL; L12120; AAA16156.1; -
DR MGD; MGI:96538; 1110ra.
DR InterPro: IPR000282; Cytok_receptor_2.
KW Receptor; Transmembrane; Glycoprotein; Signal.
FT SIGNAL 1 16
FT CHAIN 17 575
FT DOMAIN 17 241
FT TRANSLEM 242 262
FT DOMAIN 263 575
FT DISUFID 204 225
FT CARBOHYD 50 50
FT CARBOHYD 66 66
FT CARBOHYD 113 113
FT CARBOHYD 182 182
FT CARBOHYD 238 238
SQ SEQUENCE 575 AA; 64248 MW; 820B9CD576F868B7 CRC64;

Query Match 14.8%; Score 183.5; DB 1; Length 575;
Best Local Similarity 30.2%; Pred. No. 1.9e-09;

Matches 74; Conservative 34; Mismatches 92; Indels 45; Gaps 14;

QY 7 FLGFLISFLTGVA-GTOSTHSLKRGVRFQSRFHHLLMOMGRALITGSSVYFQYK 65
Db 8 FLVTISLSLEFVNGT-----ELPSPSTVWFARFQHLHWKP-IPNQSSTVYEVALK 62

Mon Jan 13 15:37:32 2003

66 IYGORQWKNKEDCWGTQELSCDLSSTQEPYVG---RVRAASAGSYSEWSMT-PRFT 121
 63 QYGNSTWNDIHCRAQALSCDLSSTQEPYVG---RVRAASAGSYSEWSMT-PRFT 122
 122 PWETKIDPPVNMNITQV---NGSLVILHAPNLPVRYOKENKNSIEDYELLY---RV 173
 123 -----VDEVILTVDSTVKAMDGIIIVGTIHP-----RPIITPAGDEYEQVFXDLRV 169
 174 FIINNSLEKEQKVEGAHRAVEIEALT-----PHSSYCVVAEIQPMLDRR-----SORSEE 225
 170 YKI--SIRKPSL-KNATKRVKQETFTLTPIGVRKCVKV---LPRLESINKAEMSEE 223
 226 RCVEI 230
 224 QCLLI 228

Query Match 13.9%; Score 173; DB 1; Length 349;
 Best Local Similarity 29.8%; Pred. No. 9.7e-09;
 Matches 70; Conservative 30; Mismatches 93; Indels 42; Gaps 12;

QY 6 CFLGFLISFFLTGVAGTOSTHESLKPQVQFQSRNFHNILOQ-----PGRALTGNSSVYF 61
 Db 4 CVAGMLGGFLVLPALGMP-----PPEKVRMNSVNFKNILQWEPVAFPKTNTL-----FT 53
 QY 62 VOYKIYQORQWKNKEDCWGTQELSCDLSSTQEPYVG---RVRAASAGSYSEWSMT-PRFT 119
 Db 54 AOYESYRSFQ-----DHCKRTASTQCDPFSHLSKYGD-----YTVRVRAELADEHSEW-VNVT 104
 QY 120 FTPWMETKIDPPVNMNITQV---NGSLVILHAPNLPVRYOKENKNSIEDYELLYRV 173
 Db 105 FCPVEDTIIGPEMQIESLAESLHLRFSAPOI-----ENEPEWTTLKNI-----YDSWAYRV 156
 QY 174 -FIINNSLEKEQKVEGAHRAVEIEALTPHSSYCVVAEIQPMLDRR-SORSEEC 227
 Db 157 QYWKNGTNEKQVQV--SPYDSEVLRNLEPWTTCIQVQGLDQNRGTGSEWSEPIC 209

RESULT 3
 TF_HUMAN
 ID TF_HUMAN STANDARD; PRT; 295 AA.
 AC F13726;
 DT 01-JAN-1990 (Rel. 13, Created)
 DT 01-JAN-1990 (Rel. 13, Last sequence update)
 DT 16-OCT-2001 (Rel. 40, Last annotation update)
 DE Tissue factor precursor (TF) (Coagulation factor III)
 GN F3.
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 OX NCBI_TaxID=9606;
 RN [1]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=89247359; PubMed=2719931;
 RA Mackman N., Morrissey J.H., Fowler B., Edgington T.S.;
 RT "Complete sequence of the human tissue factor gene, a highly
 RT regulated cellular receptor that initiates the coagulation protease
 RT cascade";
 RL Biochemistry 28:1755-1762(1989).
 RN [2]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=87260946; PubMed=3037536;
 RA Spicer E.K., Horton R., Bloem L., Bach R., Williams K.R., Guha A.,
 RA Kraus J., Lin T.C., Nemerson Y., Konigsberg W.H.;
 RT "Isolation of cDNA clones coding for human tissue factor: primary
 RT structure of the protein and cDNA";
 RL Proc. Natl. Acad. Sci. U.S.A. 84:5148-5152(1987).
 RN [3]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=87244317; PubMed=3297348;
 RA Morrissey J.H., Fakhrai H., Edgington T.S.;
 RT "Molecular cloning of the cDNA for tissue factor, the cellular
 RT receptor for the initiation of the coagulation protease cascade";
 RL Cell 50:129-135(1987).
 RN [4]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=88050796; PubMed=2823875;
 RA Scarpati E.M., Wen D., Broze G.J. Jr., Milewich J.P.,
 RA Flandermeier R.R., Siegel N.R., Sadler J.E.;
 RT "Human tissue factor: cDNA sequence and chromosome localization of

110S MOUSE
 ID 110S MOUSE STANDARD; PRT; 349 AA.
 AC Q61190;
 DT 16-OCT-2001 (Rel. 40, Created)
 DT 16-OCT-2001 (Rel. 40, Last sequence update)
 DT 15-JUN-2002 (Rel. 41, Last annotation update)
 DE Interleukin-10 receptor beta chain precursor (IL-10R-B) (IL-10R2)
 DE (Cytokine receptor class-II CRF2-4).
 GN IL10RB OR CRFB4.
 OS Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 OX NCBI_TaxID=10090;
 RN [1]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=97199375; PubMed=9047351;
 RA Gibbs V.C., Pennica D.;
 RT "CRF2-4: Isolation of cDNA clones encoding the human and mouse
 RT proteins";
 RL Gene 186:97-101(1997).
 RN [2]
 RP CHARACTERIZATION.
 RX MEDLINE=98130620; PubMed=9463407;
 RA Spencer S.D., Di Marco F., Hoolley J., Pitts-Meek S., Bauer M.,
 RA Ryan A.M., Sordat B., Gibbs V.C., Aguet M.;
 RT "The orphan receptor CRF2-4 is an essential subunit of the interleukin
 RT 10 receptor";
 RL J. Exp. Med. 187:571-578(1998).
 CC -!- FUNCTION: RECEPTOR FOR IL-10 AND IL-22. SERVES AS AN ACCESSORY
 CC CHAIN ESSENTIAL FOR THE ACTIVE IL-10 RECEPTOR COMPLEX AND TO
 CC INITIATE IL-10-INDUCED SIGNAL TRANSDUCTION EVENTS.
 CC -!- SUBCELLULAR LOCATION: Type I membrane protein.
 CC -!- SIMILARITY: CONTAINS 2 FIBRONECTIN TYPE III-LIKE DOMAINS.
 CC -!- SIMILARITY: BELONGS TO THE CLASS II CYTOKINE FAMILY OF RECEPTORS.
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation.
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC EMBL; U53696; AAC53062.1; -;
 DR MGD; MGI:109380; 1110rb.
 DR InterPro; IPR000282; Cytok_receptor_2.
 DR InterPro; IPR003961; FN_III.
 DR SMART; SM00060; FN3; 1.
 DR Receptor; Transmembrane; Glycoprotein; Signal.
 KW SIGNAL 1 19 POTENTIAL.
 FT CHAIN 20 349 INTERLEUKIN-10 RECEPTOR BETA CHAIN.
 FT DOMAIN 20 220 EXTRACELLULAR (POTENTIAL).
 FT TRANSMEM 221 241 POTENTIAL.
 FT DOMAIN 242 349 CYTOPLASMIC (POTENTIAL).
 FT

GenCore version 5.1.3
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 13, 2003, 15:28:46 ; Search time 26.0282 Seconds

(without alignments)
1828.668 Million cell updates/sec

Title: US-09-728-911-2

Perfect score: 1244

Sequence: 1 MPMKCFGLGFLISFLTGVA.....YQPMIDRRSQRSERCEVIEIP 231

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 671580 seqs, 206047115 residues

T number of hits satisfying chosen parameters: 671580

Minimum DB seq length: 0

Maximum DB seq length: 2000000000
Maximum Match 100%
Listing first 45 summaries

Database :

1: SPREMBL_21:*
2: sp_bacteria:*
3: sp_fungi:*
4: sp_human:*
5: sp_invertebrate:*
6: sp_mammal:*
7: sp_mhc:*
8: sp_organelle:*
9: sp_phage:*
10: sp_plant:*
11: sp_podent:*
12: sp_virus:*
13: sp_vertebrate:*
14: sp_unclassified:*
15: sp_virus:*
16: sp_bacteriap:*
17: sp_archaeap:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1244	100.0	231	4	096A41
2	1218	97.9	263	4	096A05
3	695	55.9	130	4	096GRO
4	336	27.0	553	4	096H84
5	336	27.0	553	4	096SH8
6	288	23.2	209	4	096SH7
7	266	21.4	574	4	096H22
8	210.5	16.9	569	11	096ND6
9	193.5	15.6	294	13	096W13
10	189.5	15.2	341	13	096Y08
11	168.5	13.3	325	4	096BU4
12	166	13.3	351	11	096VM7
13	160	12.9	442	13	096VJ9
14	158	12.7	569	13	096YH0
15	143.5	11.5	557	4	08W222
16	140	11.3	294	11	08R3Q1

17	138.5	11.1	332	6	096K86	096K86 ovis aries
18	136.5	11.0	489	4	096Y69	096Y69 homo sapien
19	127.5	10.2	508	13	096YV9	096YV9 gallus gall
20	125.5	10.1	508	13	096VX0	096VX0 gallus gall
21	124	10.0	484	4	014936	014936 homo sapien
22	114.5	9.2	332	11	063953	063953 mus musculu
23	108.5	8.7	239	4	015467	015467 homo sapien
24	108.5	8.7	331	4	096U40	096U40 homo sapien
25	98.5	7.9	608	6	096N07	096N07 monodelphis
26	98	7.9	477	11	091Y85	091Y85 mus musculu
27	97.5	7.8	674	13	090369	090369 coturnix co
28	97.5	7.8	675	13	090367	090367 gallus gall
29	97	7.8	465	11	096SH7	096SH7 rattus norv
30	95.5	7.7	2959	11	096QZ2	096QZ2 rattus norv
31	95	7.6	266	12	089190	089190 variola vir
32	95	7.6	266	12	066793	066793 ectromelia
33	93.5	7.5	1289	4	09Y2A5	09Y2A5 homo sapien
34	93	7.5	271	12	072744	072744 cowpox viru
35	93	7.5	272	12	091E03	091E03 cowpox viru
36	92.5	7.4	1155	17	087G28	087G28 methanosarc
37	91.5	7.4	351	17	087G57	087G57 methanosarc
38	91	7.3	266	12	08V2J5	08V2J5 vaccinia vi
39	91	7.3	272	12	09JF43	09JF43 vaccinia vi
40	91	7.3	389	13	096E23	096E23 xenopus lae
41	91	7.3	442	13	096E22	096E22 xenopus lae
42	90	7.2	848	2	09K1B4	09K1B4 porphyromon
43	90	7.2	1028	11	062682	062682 rattus norv
44	89	7.2	1028	11	007409	007409 mus musculu
45	88	7.1	266	12	089543	089543 variola vir

ALIGNMENTS

RESULT 1
Q96A41 PRELIMINARY; PRT; 231 AA.

AC Q96A41; 01-DEC-2001 (TREMURel. 19, Created)
DT 01-DEC-2001 (TREMURel. 19, Last sequence update)
DT 01-MAR-2002 (TREMURel. 20, Last annotation update)
DE Soluble cytokine class II receptor, short isoform precursor
DE (Interleukin-22-binding protein CRF2-10) (Class II cytokine receptor)
DE CRF2-S1 OR IL22BP OR IL22RA2 OR IL-22BP.
GN Homo sapiens (Human)
OS Homo sapiens
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OC NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=MAMMARY GLAND;
RX MEDLINE=21518574; PubMed=11607789;
RA Grenberg B.H., Schoenmeyer A., Weiss B., Toschi L., Kunz S.,
RT Volk K., Asadullah K., Sabat R.;
RT "A novel, soluble homologue of the human IL-10 receptor with
RT preferential expression in placenta.";
RL Genes Immun. 2:329-334(2001).
[2]
RP SEQUENCE FROM N.A.
RX MEDLINE=21286453; PubMed=11390454;
RA Kotenko S.V., Izotova L.S., Mironichenko O.V., Esterova E.,
RT Katsenhebe H., Donnelly R.P., Pestka S.;
RT "Identification, cloning, and characterization of a novel soluble
RT receptor that binds IL-22 and neutralizes its activity.";
RL J. Immunol. 166:7096-7103(2001).
[3]
RP SEQUENCE FROM N.A.
RX MEDLINE=21396522; PubMed=11481447;
RA Xu W., Presnell S.R., Parrish-Novak J., Kindsvogel W., Jaspers S.,
RA Chen Z., Dillon S.R., Gao Z., Gilbert T., Madden K., Schlutsmeyer S.,
RA Yao L., Whitmore T.E., Chandrasekhar Y., Grant F.J., Maurer M.,
RA Jelinek L., Storey H., Brender T., Hammond A., Topouzis S.,

Db 121 TPWME 125

RESULT 4

09UH4 PRELIMINARY; PRT; 553 AA.

AC 09UH4: 01-MAY-2000 (Tremblrel. 13, Created)
 DT 01-MAY-2000 (Tremblrel. 13, Last sequence update)
 DT 01-MAR-2002 (Tremblrel. 20, Last annotation update)
 DE Class II cytokine receptor ZCYTOR7.
 GN ZCYTOR7.
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
 NCBI_TaxID=9606;
 RN [1]
 RP SEQUENCE FROM N.A.
 RA Lok S., Kho C., Jelmberg A., Adams R., Whitmore T., Farrah T.,
 R. O'Hara P.,
 RL Homo sapiens cytokine receptor homolog."
 RL Submitted (OCT-1999) to the EMBL/GenBank/DBJ databases.
 RN [2]
 RP SEQUENCE FROM N.A.
 RA Presnell S., Gilbert T., Whitmore T., Foster D., Hart C., Lehner J.,
 RA Martinez T., Hoffman R., O'Hara P.,
 RL Submitted (SEP-1999) to the EMBL/GenBank/DBJ databases.
 DR EMBL: AF184971; AAF01320.1; -.
 DR HSP: P13726; 2HPT.
 DR InterPro: IPR000282; Cytok_receptor_2.
 DR InterPro: IPR001187; Tissue_factor.
 DR Pfam: PF01108; Tissue_fac; 1.
 KW Receptor.
 SQ SEQUENCE 553 AA; 62533 MW; 7C23C8543B114659 CRC64;

Query Match 27.0%; Score 336; DB 4; Length 553;
 Best Local Similarity 37.2%; Pred. No. 9.1e-24;
 Matches 74; Conservative 33; Mismatches 90; Indels 2; Gaps 2;

QY 30 KPOVQFOSRNFHNILOMOPGRALTGNSSVFYQYKIYQGRQWKKEDEGQELSCDIT 89
 DB 39 KPNITFLSINMKNVLOMTPEGLQGVKTYVYQYKIYQGRQWKKEDEGQELSCDIT 89
 QY 90 SETSDIEPIYGRVRAASAGSYSEWMTPTPTWETKIDPPVNNITQVNSLVIILHAP 149
 DB 99 AETSDYEHQYAKVAKIWTGKCSKMAESGRFPLETOIGPEVALITDEKSISVLTAP 158
 QY 150 NLPRYQKEKNVSIIDY-ELLYRVIINNSLEKQKVEGAHRAVEIALTPHSSYCV 208
 DB 159 EKKMKNPELIPVSMQOYISNLTKNVSVLNTKSNRTWSQCVTNHTLV-LTWLEPNTLYCVH 217
 QY 209 AEIYQPMIDRSQSRSEERC 227
 DB 218 VESFVPGPPRRAQPSSEKQC 236

RESULT 5

096SH8 PRELIMINARY; PRT; 553 AA.

AC 096SH8: 01-DEC-2001 (Tremblrel. 19, Created)
 DT 01-DEC-2001 (Tremblrel. 19, Last sequence update)
 DT 01-JUN-2002 (Tremblrel. 21, Last annotation update)
 DE BA204P2.1.1 (interleukin 20 receptor alpha, isoform 1).
 GN IL20RA.
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
 NCBI_TaxID=9606;
 RN [1]
 RP SEQUENCE FROM N.A.
 RA Griffiths C.;

RL Submitted (MAY-2001) to the EMBL/GenBank/DBJ databases.
 DR EMBL: AL135902; CAC38375.1; -.
 DR InterPro: IPR000282; Cytok_receptor_2.
 DR InterPro: IPR003961; RN_III.
 DR InterPro: IPR001187; Tissue_factor.
 DR Pfam: PF01108; Tissue_fac; 1.
 DR SMART: SM00060; FN3; 1.
 KW Receptor.
 SQ SEQUENCE 553 AA; 62485 MW; D5C2621FDC848328 CRC64;

Query Match 27.0%; Score 336; DB 4; Length 553;
 Best Local Similarity 37.2%; Pred. No. 9.1e-24;
 Matches 74; Conservative 33; Mismatches 90; Indels 2; Gaps 2;

QY 30 KPOVQFOSRNFHNILOMOPGRALTGNSSVFYQYKIYQGRQWKKEDEGQELSCDIT 89
 DB 39 KPNITFLSINMKNVLOMTPEGLQGVKTYVYQYKIYQGRQWKKEDEGQELSCDIT 89
 QY 90 SETSDIEPIYGRVRAASAGSYSEWMTPTPTWETKIDPPVNNITQVNSLVIILHAP 149
 DB 99 AETSDYEHQYAKVAKIWTGKCSKMAESGRFPLETOIGPEVALITDEKSISVLTAP 158
 QY 150 NLPRYQKEKNVSIIDY-ELLYRVIINNSLEKQKVEGAHRAVEIALTPHSSYCV 208
 DB 159 EKKMKNPELIPVSMQOYISNLTKNVSVLNTKSNRTWSQCVTNHTLV-LTWLEPNTLYCVH 217
 QY 209 AEIYQPMIDRSQSRSEERC 227
 DB 218 VESFVPGPPRRAQPSSEKQC 236

RESULT 6

096SH7 PRELIMINARY; PRT; 209 AA.

AC 096SH7: 01-DEC-2001 (Tremblrel. 19, Created)
 DT 01-DEC-2001 (Tremblrel. 19, Last sequence update)
 DT 01-MAR-2002 (Tremblrel. 20, Last annotation update)
 DE BA204P2.1.3 (interleukin 20 receptor alpha, isoform 3).
 GN IL20RA.
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
 NCBI_TaxID=9606;
 RN [1]
 RP SEQUENCE FROM N.A.
 RA Griffiths C.;
 RL Submitted (MAY-2001) to the EMBL/GenBank/DBJ databases.
 DR EMBL: AL135902; CAC38376.1; -.
 DR InterPro: IPR000282; Cytok_receptor_2.
 KW Receptor.
 SQ SEQUENCE 209 AA; 23616 MW; 467AB77B3840361 CRC64;

Query Match 23.2%; Score 288; DB 4; Length 209;
 Best Local Similarity 37.2%; Pred. No. 1.1e-19;
 Matches 61; Conservative 29; Mismatches 72; Indels 2; Gaps 2;

QY 30 KPOVQFOSRNFHNILOMOPGRALTGNSSVFYQYKIYQGRQWKKEDEGQELSCDIT 89
 DB 39 KPNITFLSINMKNVLOMTPEGLQGVKTYVYQYKIYQGRQWKKEDEGQELSCDIT 89
 QY 90 SETSDIEPIYGRVRAASAGSYSEWMTPTPTWETKIDPPVNNITQVNSLVIILHAP 149
 DB 99 AETSDYEHQYAKVAKIWTGKCSKMAESGRFPLETOIGPEVALITDEKSISVLTAP 158
 QY 150 NLPRYQKEKNVSIIDY-ELLYRVIINNSLEKQKVEGAHRAVEIALTPHSSYCV 208
 DB 159 EKKMKNPELIPVSMQOYISNLTKNVSVLNTKSNRTWSQCVTNHTLV-LTWLEPNTLYCVH 217

RESULT 7

09HB22 PRELIMINARY; PRT; 574 AA.

Mon Jan 13 15:37:33 2003

```

AC Q9HB22; 2001 (TREMBLrel. 16, Created)
DT 01-MAR-2001 (TREMBLrel. 16, Last sequence update)
DT 01-MAR-2001 (TREMBLrel. 19, Last annotation update)
DE IL-22 receptor.
GN Homo sapiens (Human).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=20469498; PubMed=10875937;
RA Xie M.H., Aggarwal S., Ho W.H., Foster J., Zhang Z., Stinson J.,
RA Wood W.I., Goddard A.D., Gurney A.L.;
RT "Interleukin (IL)-22, a Novel Human Cytokine That Signals through the
RT Interferon Receptor-related Proteins CRF2-4 and IL-22R.";
RL J. Biol. Chem. 275:31335-31339(2000).
DR EMBL; AF286095; AAG22073.1; -.
DR HSP; P13726; ITHF.
DR InterPro; IPR000282; Cytok_receptor_2.
KW Receptor.
SQ SEQUENCE 574 AA; 62977 MW; C179C7085C6F3420 CRC64;

Query Match 21.4%; Score 266; DB 4; Length 574;
Best Local Similarity 33.0%; Pred. No. 4.9e-17; Indels 16; Gaps 5;
Matches 69; Conservative 31; Mismatches 93;

QY 21 GTOSTHSLKP-----ORVQFQSRNHNILQWQGRALTGNSVYVQYKIQGRQWKNKE 76
DB 11 GSUAHAPEPSLLQHVRFQSSNFENILTWDSGPGTDP-TVYSIEYKTYGERDWVAKK 69
QY 77 DCWGTQSLCDLTSSETSDIQEYVGRVRAASAGSYSEWSMTPTFTPMWETKIDPPVMNIT 136
DB 70 GCQIRTKSCNLTVECTGNLTLYAVRTAVSAGRSATKMTDRFSLQHTLTKPPDVTCI 129
QY 137 QVNGSLVLHAPNLPVRYQKKNVSTED-YVELLYRVFTIINNSLEKEQKVE-----GAH 191
DB 130 SKVRSIQMIVHTPTTPTRAGDGHRLTLEDIFDLFYHLELVN-----RTYQMHLLGGKQ 183
QY 192 RAVIEALTPHSSYCVVAEIQPMLDRS 220
DB 184 REYEFGLTPDTEFLGTIMICVPTWAKES 212

RESULT 8
Q99ND6 PRELIMINARY; PRT; 569 AA.
AC Q99ND6;
DT 01-JUN-2001 (TREMBLrel. 17, Created)
DT 01-JUN-2001 (TREMBLrel. 17, Last sequence update)
DT 01-MAR-2002 (TREMBLrel. 20, Last annotation update)
DE Interleukin-10 receptor, alpha chain precursor.
GN IL-10RA.
OS Rattus norvegicus (Rat).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
OX NCBI_TaxID=10116;
RN [1]
RP SEQUENCE FROM N.A.
RX TISSUE=PERIPHERAL BLOOD;
RA Ward H., Vignas S., Poole S., Bristow A.F.;
RT "The rat interleukin-10 receptor: cloning and sequencing of cDNA
RT coding for the alpha-chain protein sequence, and demonstration by
RT western blotting of expression in rat brain.";
RL Cytokine 0.0-0.0(0).
DR EMBL; AJ305049; CAC24567.1; -.
DR InterPro; IPR000282; Cytok_receptor_2.
KW Receptor; Signal.
FT CHAIN 1 16 POTENTIAL.
FT CHAIN 17 569 INTERLEUKIN-10 RECEPTOR.
SQ SEQUENCE 569 AA; 63526 MW; 2354FD61DB351BD2 CRC64;

Query Match 15.6%; Score 193.5; DB 13; Length 294;
Best Local Similarity 29.5%; Pred. No. 2e-10; Indels 45; Gaps 13;
Matches 72; Conservative 37; Mismatches 90;

QY 9 GFLIS--PFLTGAGTQSTHSLKPQVQFQSRNHNILQWQGRALTGNSVYVQYKI 66
DB 11 GVLLSVLFTTGAAGEDYFPEAMD---VQVSVNNFKILTWP-----EPTNYTYVEFSR 63
QY 67 YGQQRQWKNKDCWGTQSLCDLTSSETSDIQEYVGRVRAASAGSYSE-----113
DB 64 VGKDRQRNPH-CIRSSRTECDLTNELNQLQTY-----SADLSLPLPGVTSDLVEFP 115
QY 114 WSMTPRTFTPMWETKIDPPVMNITQVNGSLVLHAPN-LPVRYQKKNVSIEDYY--ELL 170
DB 116 YTRAERFSYKHTKIGGPAFKIVQSEDKTKMTLHQDPLTPLYKDDQLLTIRDFKSDLK 175
QY 171 YRVFTIN--NSLEKEQKVEGAHRAVEIEALTPHSSYCVVAEIQPMLDRSQR-----S 223

Query Match 16.9%; Score 210.5; DB 11; Length 569;
Best Local Similarity 28.0%; Pred. No. 1e-11; Indels 51; Gaps 11;
Matches 71; Conservative 36; Mismatches 96;

QY 1 MPMKHCFGLGFLISFFLTGAGTQSTHSLKPQVQFQSRNHNILQWQ--PGRALTGNS 58
DB 1 MLPR--LLPFLVSISLSLGFRAHGTLPSPSSVWFEEAFFOHILRWMSIPNQS---EST 55
QY 59 VYFQYKIQGRQWKNKDCWGTQSLCDLTSSETSDI--QEPYVGRVRAASAGSYSEWSM 116
DB 56 YVEVALKKYGTSIWKDHIHCSKAQTLSCDLTTSTLDLYHSSGYRARVRAVDNSQSNWTI 115
QY 117 T-PRFTPMWETKIDPPVMNITQV-----NGSLVLHAPNLPVRYQKKNVSIEDYYE-- 168
DB 116 TETRT-----VDEVILTVDSTVTVKVSNGFIYGTTHPP-----RPNLVPGVDEYEQI 162
QY 169 ----LLYRVFT-----INNSLEKEQKVEGAHRAVEIEALTPHSSYCVVAEIQPML 216
DB 163 FTHRIIRVCIKRFSEQKNITKIVEQNFTELVPKRM-----RKFCVKVMPHVESR 213
QY 217 DRRQRSEERCEI 230
DB 214 INKAEWSEEQCLHV 227

RESULT 9
Q90W13 PRELIMINARY; PRT; 294 AA.
AC Q90W13;
DT 01-DEC-2001 (TREMBLrel. 19, Created)
DT 01-DEC-2001 (TREMBLrel. 19, Last sequence update)
DT 01-MAR-2002 (TREMBLrel. 20, Last annotation update)
DE Tissue factor precursor.
GN TF.
OS Oncorhynchus mykiss (Rainbow trout) (Salmo gairdneri).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Actinopterygii; Neopterygii; Teleostei; Euteleostei;
OC Protacanthopterygii; Salmoniformes; Salmonidae; Oncorhynchus.
OX NCBI_TaxID=8022;
RN [1]
RP SEQUENCE FROM N.A.
RX TISSUE=HEAD KIDNEY;
RA Sangrador-Vegas A., Smith T.J.;
RT "Molecular cloning of rainbow trout (Oncorhynchus mykiss) tissue factor
RT precursor by use of suppression subtractive hybridisation.";
RL Submitted (NOV-2000) to the EMBL/GenBank/DBJ databases.
DR EMBL; AJ295167; CAC82787.1; -.
DR InterPro; IPR000282; Cytok_receptor_2.
DR InterPro; IPR001187; Tissue_factor.
DR Pfam; PF01108; Tissue_fac; 1.
KW Signal.
FT CHAIN 1 25 POTENTIAL.
FT CHAIN 26 294 TISSUE FACTOR.
SQ SEQUENCE 294 AA; 33404 MW; 105DDDA107E54EDE CRC64;

Query Match 15.6%; Score 193.5; DB 13; Length 294;
Best Local Similarity 29.5%; Pred. No. 2e-10; Indels 45; Gaps 13;
Matches 72; Conservative 37; Mismatches 90;

QY 9 GFLIS--PFLTGAGTQSTHSLKPQVQFQSRNHNILQWQGRALTGNSVYVQYKI 66
DB 11 GVLLSVLFTTGAAGEDYFPEAMD---VQVSVNNFKILTWP-----EPTNYTYVEFSR 63
QY 67 YGQQRQWKNKDCWGTQSLCDLTSSETSDIQEYVGRVRAASAGSYSE-----113
DB 64 VGKDRQRNPH-CIRSSRTECDLTNELNQLQTY-----SADLSLPLPGVTSDLVEFP 115
QY 114 WSMTPRTFTPMWETKIDPPVMNITQVNGSLVLHAPN-LPVRYQKKNVSIEDYY--ELL 170
DB 116 YTRAERFSYKHTKIGGPAFKIVQSEDKTKMTLHQDPLTPLYKDDQLLTIRDFKSDLK 175
QY 171 YRVFTIN--NSLEKEQKVEGAHRAVEIEALTPHSSYCVVAEIQPMLDRSQR-----S 223

```